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ABSTRACT 
Lung cancer is the leading cause of cancer mortality for men and women in the 
United States, with a high mortality rate and a five-year survival rate of less than 
15%.Cancer ranks second as a cause of death for Americans after cardiovascular disease. 
The American Cancer Society (ACS) reported 171,900 new cases of lung cancer for 2003 
(ACS, 2003). Peripheral adenocarcinoma (PAC) of the lung has increased dramatically 
over the last 20 years and is the leading histological type of lung cancer in smokers and 
nonsmokers in industrialized countries, including the United States. Among the four 
main histological lung caner types (small-cell carcinoma, squamous-cell carcinoma, 
adenocarcinoma and large-cell carcinoma), adenocarcinoma that is derived from small­
airway epithelia with features of Clara cells accounts for about 35-40% of all lung cancer 
cases. Unlike other .. histological lung cancer types, adenocarcinoma also develops in a 
significant number of non-smokers. 
Smoking remains the greatest contributor to the development of lung cancer, with 
90% of all lung cancer cases estimated to be smoking related. Cigarette smoke contains 
about 4,000 toxic chemicals including the highly carcinogenic nitrosamine, 4-
(methylnitrosamino)-1- (3-pyridyl)-1-butanone (NNK). NNK is the most potent 
carcinogen in laboratory animals and has therefore been implicated as a significant cause 
of tobacco-associated cancers in human. 
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Dietary and genetically determined factors appear to play an important role in 
modulating individual susceptibility to smoking-associated cancer and are closely linked 
to the chemoprevention approach. 
Chemoprevention is defined as the use of naturally occurring or synthetic agents 
to prevent, inhibit or reverse the process of carcinogenesis. This relatively new approach 
of cancer prevention has precedence in other areas of medicine such as cardiovascular 
diseases. 
Earlier studies have shown the presence of a �-adrenergic/cAMP growth­
regulating pathway in PAC. Therefore, �-adrenergic stimulants in various drugs that are 
used for the treatment of chronic respiratory and cardiovascular diseases have been 
proposed as potential risk factors for the development of PAC. Furthermore, little is 
known about the downstream effectors of this pathway and their role in the regulation of 
proliferation of PAC and their normal cells of origin. 
Using assays for the assessment of cAMP production, PKA activity, MAPK 
activation, CREB activation, and cell proliferation, we have identified a mitogenic 
pathway, which activates cAMP in cell lines derived from human peripheral 
adenocarcinomas that express features of Clara cells and their normal cells of origin, 
small airway epithelial cells (SAEC). 
�-carotene and a substance contained in green and black tea, theophylline are 
widely believed to have cancer preventive effects. However, our current data show that 
each of these agents increases cAMP/PKA activity, ERKl/2 and CREB resulting in a 
significant growth stimulation of PAC and SAEC. Accordingly, and pending on the exact 
level targeted by a given chemopreventive agents, such treatments will likely promote the 
X 
development of PAC. While some of these agents may inhibit the metabolic activation of 
tobacco carcinogens, such as NNK, former smokers who start chemoprevention will not 
benefit from such effects as they start chemopreventive treatment after discontinuation of 
exposure to tobacco carcinogens. Currently, there is no agent that has been shown to be 
effective in preventing lung cancer. Accordingly, the most effective prevention of lung 
cancer is never to smoke and to avoid exposure to second hand smoke. 
Our study findings suggest that the widely advertised cancer preventive agents 
that currently are still tested by several laboratories as "chemopreventive" agents such as 
�-carotene and a substance contained in green and black tea, theophylline are unsafe to be 
used by smokers or by ex-smokers due to their tumor promoting effects via stimulation of 
cAMP on initiated cells of Clara cell lineage. 
Xl 
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Peripheral adenocarcinoma (PAC) of the lung has increased dramatically over the 
last 20 years. PAC is today the leading histological type of lung cancer death in smokers 
and non-smokers in both men and women of industrialized countries, with a high 
mortality rate and five-year survival rate of less than 15% after diagnosis (1-4). 
According to a recent report by the United States Surgeon General, lung cancer in women 
has increased by 600% since the 1950s and has reached epidemic levels (5, 6). Since the 
late 1980s, lung cancer in women has surpassed breast cancer as the leading cause of 
cancer death (7). The American Cancer Society (ACS) reported 171,900 new cases of 
lung cancer for 2003 and 173,770 new cases and 160,440 deaths are expected in the 
United States in the year 2004 (8). Lung cancer ranks as a second cause of death after 
cardiovascular disease (9). 
The most important risk factor for lung cancer is cigarette smoking, which 
accounts for 80-90% of all cases (10, 17). The only effective means of lung cancer 
prevention is never to smoke or giving up smoking (11). Lung cancer is usually detected 
at an advanced stage of development when metastasis and drug resistance have already 
developed (12). The prognosis has not been improved by chemoprevention because of the 
lack of an effective systemic treatment (13, 14) .  The incidence of lung cancer has slowly 
decreased among men in developed countries, whereas it has increased in women (10). 
However, lung cancer is the main cause of cancer death in both sexes, with an annual 
mortality rate of 91 % ( 15). 
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Among the four main histological lung cancer types (small cell carcinoma, 
squamous cell carcinoma (SQC), adenocarcinoma, and large cell carcinoma), 
adenocarcinoma that is derived from small airway epithelium with feature of Clara cells 
accounts for about 35-40% of all lung cancer cases ( 16). Small cell carcinoma and 
squamous cell carcinoma are developing exclusively in smokers (3, 4) while PAC is 
additionally found in a significant numbers of non-smokers (3) . Moreover, PAC 
frequently develops in patients under the age of 50 as opposed to other types of lung 
cancer that are typically diagnosed in patients of age 60 and older ( 18). 
An alarming increase in teenage smoking will without doubt, raise the lung cancer 
epidemic even farther in the years to come (19) . The development of effective treatments 
that prevent the progression of precancerous lesions or early stage lung cancers into overt 
cancers in smokers, who quit, are therefore urgently needed. Mouse models are widely 
used in preclinical studies to test the efficacy of novel chemopreventive agents. Studies in 
our laboratory have shown that the growth of human PAC cell lines of Clara cell lineage 
(PACC) in vitro and of PACC induced in hamsters by the nicotine-derived nitrosamine, 
4-(methylnitrosamino )-1-(3-pyridyl)-1-butanone (NNK) are regulated by beta-adrenergic 
receptors through the activation of cAMP (20-23). These experiments also demonstrated 
that the in vitro and in vivo growth of P ACC is promoted by the beta-adrenergic agonist 
epinephrine and by the cyclic nucleotide phosphodiesterase inhibitor theophylline (20-
23) . These findings suggest an important role of beta-adrenergic receptors and their 
downstream effector cyclic adenosine monophosphate ( cAMP) in the growth regulation 
of PACC. By contrast, studies of PAC derived from alveolar type II cells in mice and in 
human squamous cell carcinoma (SQC) have identified signaling via the epidermal 
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growth factor receptor (EGFr) pathway and a PKC-mediated pathway as an important 
growth regulating events (24-30). 
The major concern with respect to preclinical lung cancer prevention is the fact 
that, these pathways appear to be antagonistic at the level of cAMP /PKA. While agents 
that activate or increase intracellular cAMP may inhibit the EGF or PKC pathways via 
inhibiting Raf-1, these may promote �-adrenergic, cAMP- mediated growth regulating 
pathways. Accordingly, chemopreventive agents that interact with �-adrenergic/cAMP 
signaling pathway treatment may prevent the development of alveolar type II cell 
carcinoma or squamous cell carcinoma while promoting the development of P ACC. 
In the 1990s, a comprehensive international chemoprevention trial with �­
carotene and retinoids was conducted in smokers and ex-smokers ( carotene and retinoid 
efficacy trials, CARET). This trial was based on preclinical studies that had identified 
significant chemopreventive effects of �-carotene and retinoids on rodent 
tracheobronchial SQC (31 ). Five years into the trial, this study had to be discontinued due 
to a 46% increase in lung cancer mortality and a 26% increase in cardiovascular mortality 
in groups receiving beta-carotene and retinyl palmitate (14, 32-36). 
Another popular "chemopreventive" agent, green tea, has shown mixed results in 
epidemiological studies with some reports demonstrating a reduction in lung cancer risk 
(37-42, 44), while others reported no effect or even promoting effects on lung cancer (40, 
43, 45-49). Green tea contains significant amounts of theophylline which, due to its 
inhibiting effects on phosphodiesterase, increases intracellular cAMP (34 ). Because 
P ACC and cardiovascular function are both under �-adrenergic control and both diseases 
were presented in the caret trial (20-23), the hypothesis of the current project is that �-
4 
carotene and theophylline (which is contained in tea and asthma medications) promote 
the growth of PACC via their documented ability to increase intracellular cAMP (33, 34-
36). 
Using assays for the assessment of cAMP production, PKA activity, MAPK 
activation, CREB activation and cell proliferation. This project has characterized cAMP, 
PKA, CREB and ERK 1 /2 as components of a mitogenic signal transduction pathway in 
cell lines derived from human P ACC and their normal cells of origin, small airway 
epithelial cells (SAEC). The selective nature of this growth-promoting pathway on P ACC 
and SAECs was confirmed by studies in a cell line derived from human large airway 
epithelial cells (BEAS-2B). Contrary to PACC and SAECs, these cells responded with a 
growth inhibition to �-carotene. 
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Working hypothesis 
The central hypothesis of this project is that the pro-vitamin A, P-carotene and a 
substance contained in green and black tea such as theophylline, promote the growth of 
the human PACC cell line NCI-H322 and their normal cells of origin, SAEC. Data 
generated by this project supported the hypothesis and showed that both of these 
"chemopreventive" agents stimulated cell grown in both cell systems, an effect mediated 
by activation of cAMP,PKA,CREB and ERKl/2. 
Specific aims 
1 .  To test the hypothesis that P-carotene stimulates the growth of pulmonary 
adenocarcinoma (PAC) cells and their normal cells of origin, small airway 
epithelial cells (SAEC), and to identify signal transduction components involved 
in this effect. 
2. To test the hypothesis that theophylline stimulates the growth of pulmonary 
adenocarcinoma (PAC) cells and their normal cells of origin, small airway 
epithelial cells (SAEC), and to identify signal transduction components involved 
in this effect. 
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I. Lung cancer overview 
At the beginning of the 20th century, lung cancer was considered a rare disease ( 1 ,  
2 ,  27). However, since then the incidence of lung cancer has dramatically increased to 
become one of the most common malignancies and the leading cause of cancer death 
with a high mortality rate and five-year survival rates of less than 1 5% in developed 
countries (3 , 4). New lung cancer cases diagnosed throughout the world in 2002 were 
estimated to be approximately 1 .2 million and more than 90% of these cases are expected 
to die from this disease (5 , 6). 
Approximately 1 ,334, 1 00 new cases of cancer were diagnosed and approximately 
556,500 died from cancer in the United States in the year of 2003 (7). Lung cancer was 
the second leading type among new cancer cases ( 1 7 1 ,900; 1 3% of the total) and the first 
in cancer death ( 1 57,200; 28% of the total) in the United States (7). For the year 2004, 
1 73,770 new cases of lung cancer and 1 60,440 deaths are expected in the United States 
(8, 9) . Unfortunately, the National Cancer Institute' s  stated goal of a 50% reduction in 
overall cancer mortality by the year 2000 has not been met and the death rates from some 
of the common cancers continue to rise ( 10). In addition, the total annual direct and 
indirect costs of cancer care in the United States have been estimated at more than $96 
billion ( 1 1) .  The death rate for lung cancer exceeded the combined total for breast, 
prostate, and colon cancer in developed countries (7, 12, 1 3). It is the most frequently 
diagnosed cancer type and the most common cause of cancer deaths in males and females 
in the world. This trend is also expected to continue for many years ( 14). The 
convergence of lung cancer death rates among men and women born after 1 960s support 
1 3  
the idea that males and females may be equally susceptible to developing lung cancer 
from a given amount of cigarette smoking, years of smoking, earlier age of onset, degree 
of inhalation, tar and nicotine content, and use of unfiltered cigarettes. Lung cancer in 
women has increased by 600 % since 1950 and has reached epidemic levels (7, 4, 15), an 
effect likely associated with the simultaneous observed increase of women who smoke. 
Lung cancer has surpassed breast cancer as leading cause of cancer death in women since 
the late 1980s (13). The birth-cohort pattern of lung cancer mortality after 1950 appears 
to reflect the early impact of teenage cigarette smoking on lung cancer risk on people 
under the age of 45 years (16). Before that, lung cancer was a rare disease in individuals 
under 40 years of age. Lung cancer is most frequently diagnosed in patients 50-75 years 
of age, and the incidence is higher among patients in 65-75 years old than in 55-64 years 
old group ( 17). In addition to that, individuals who stop smoking after the age of 50 may 
retain a substantial risk for lung cancer life-long (18, 19). 
Unfortunately, 1 ung cancer is usually diagnosed after the development of 
metastasis and drug resistance (20). Despite improvement in the diagnosis and treatment, 
the mortality rate remains higher than 95% within one year of diagnosis (21, 22). 
A large number of risk factors have been identified for the development of lung 
cancer, such as cigarette smoking, airflow obstruction, and exposure to asbestos, radon, 
arsenic, ionizing radiation, haloethers, polycyclic aromatic hydrocarbons, and nickel (23). 
Cigarette smoking is the single most extensively documented risk factor for lung cancer, 
accounting for - 90% of cases in men and 70-85% of cases in women (23-28, 20). 
Genetic risk factors contribute to an individual's susceptibility to lung cancer, which is 
illustrated by the fact that more than 16% of long-term smokers will develop lung cancer 
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(29). So far, a recent study reported a relationship between environmental tobacco smoke 
exposure and increased lung cancer risk among nonsmoking women with a common 
genetic deficiency in glutathione S-transferase Ml (GSTMl)  enzymatic activity because 
of a genetic polymorphism in the GSTMl gene (30). Life style factors such as diet are 
also thought to be important in the modulation of lung cancer risk (29). 
The World Health Organization (WHO) distinguishes two major lung cancer 
families: non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). 
Among the family of NSCLC, adenocarcinoma (35-40%), squamous cell carcinoma (25-
30%) and large cell carcinoma ( 10-1 5%) are recognized. Small cell lung cancer often 
responds to chemotherapy but then relapses while NSCLC is usually non-responsive (3 1 ). 
Pulmonary adenocarcinoma tends to grow very fast (32). The tumor grows along 
the alveoli and the tumor cells are bigger than normal cells and tend to cluster together 
and exhibit epithelial cells (32). It has been suggested that pulmonary adenocarcinoma 
PAC be reclassified into five cells types: bronchial surface epithelial cell type, with little 
or no mucus, goblet cell type, Clara cell type, type II alveolar epithelial cell type, and 
bronchial gland cell type (33). On the other hand, it has been suggested to classify PAC 
into: hobnail cell type, columnar/cubical cell type, polygonal cell type, and goblet cell 
type (34). Also in 1 999, the WHO classified PAC into five subtypes; acinar, papillary, 
bronchioalveolar carcinoma, solid adenocarcinoma with mucin, and adenocarcinoma of 
mixed cell type (35). 
PAC has risen dramatically during the last three decades from a very rare type of 
lung cancer to be the leading type of lung cancer today (2, 28). PAC accounts for about 
60% of all lung cancer cases (2, 28, 36, 3 8) and is particularly prominent in women and 
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African Americans (37). In the near future, this trend of PAC is expected to cover many 
geographical regions ( 1 ). It has been estimated that the mortality from adenocarcinoma 
will increase world-wide in contrast to squamous cell carcinoma and small-cell 
carcinoma for which a decrease is expected. 
PAC is the only histological lung cancer type that develops in a significant 
number of non-smoking individuals implying, that additional factors other than smoking 
contribute to the continued rise of this cancer type. Studies by Park et al. 1995 (39) and 
Schuller et al. 1999 ( 40) showed that the growth of PAC of Clara cell linage in vitro and 
in an animal model is under beta-adrenergic control and that the tobacco-specific 
carcinogen NNK [ 4-(methylnitrosamino )-1-(3-pyridyl)-1-butanone] is the most potent 
stimulator of this proliferative pathway. In addition to that, the chronic treatment of 
existing respiratory diseases such as asthma and chronic obstructive pulmonary disease 
(COPD) by �-adrenergic stimulators might play a significant role in the PAC epidemic. 
For instance, COPD is one of the most common respiratory conditions of adults in the 
developed world, which encompasses both chronic bronchitis and emphysema ( 41 ). In 
fact, patients with COPD should be monitored carefully for lung cancer ( 42) . 
An alarming increase among teenage smoking will, without doubt, increase the 
lung epidemic even farther in the years to come (16) . The developments of effective 
treatments that prevent progression of precancerous lesions, or early stage lung cancers, 
into overt cancer in smokers, who quit, are therefore urgently needed. Mouse models are 
widely used in preclinical studies to test the efficacy of novel chemopreventive agents. 
On the other hand, studies of Clara cell-derived PAC induced by NNK in hamsters have 
shown that these lung tumors express �-1 and �-2 adrenergic receptors and that their 
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growth is promoted by the �-adrenergic agonist epinephrine and by the cyclic nucleotide 
phosphodiesterace inhibitor theophylline ( 43, 44, 45). Those findings suggest an 
important role of �-adrenergic receptors and their downstream effector cyclic adenosine 
monophosphate ( cAMP) in the growth regulation of lung tumors of Clara cell lineage. In 
contrast to the hamster, NNK-induced PAC in mice is of alveolar type II cell lineage and 
their growth is inhibited by agents that stimulate cAMP ( 46-51, 20). Chemopreventive 
agents that stimulate �-adrenergic/cAMP signaling may therefore prevent the 
development of lung cancer in mice while promoting the development of P ACC in 
hamster and man. In support of this hypothesis we have recently shown that green tea 
which contains the phosphodiesterase inhibitor theophylline as well as injections with 
theophylline have strong growth promoting effects on experimentally induced PACC in 
hamsters ( 45). 
II. Chemoprevention (CP) 
Currently, in the United States and Canada alone, there are approximately 50 
million former smokers and 50 million current smokers (52). As a result of this large 
population of people at risk, an alternative cancer control method such as 
chemoprevention needs to be developed to reduce lung cancer mortality, especially for 
smokers who have followed medical advice to give up smoking. Michael Sporn was the 
first researcher who described chemoprevention (53) in 1976 and defined it as "the use of 
17 
specific natural or synthetic chemical agents to reverse, suppress or prevent carcinogenic 
progression to invasive cancer." Proof of principle studies by Ki Hong and co-workers 
(54-56) showed that chemoprevention could prevent cancer in the upper aerodigestive 
tract. Around 2000 natural and synthetic agents have been shown in experimental 
systems to have chemopreventive activity. Vitamin A was first noted to be an essential 
nutrient in 1913, while in 1925 vitamin A deficiency was reported to be associated with 
changes in epithelial histology. Since that time, vitamin A deficiency has been associated 
with bronchial metaplasia and an increased incidence of cancer (57-61). The pro-vitamin 
A, �-carotene, is also one of the most widely studied chemopreventive agents that has 
been tested in clinical trials (65). Chemoprevention trials for lung cancer have been 
carried out in phase III clinical trials for over a decade with mostly negative results ( 62-
66). Although, a combination of beta-carotene and vitamin A supplement for an average 
of four years had no benefit and may have had an adverse effect on the incidence of lung 
cancer and on the risk of death from lung cancer, cardiovascular disease, and any cause in 
smokers and workers exposed to asbestos (62). 
Chemopreventive agents (CPA) may affect cellular proliferation, differentiation, 
apoptosis and tumor angiogenesis (67). In primary prevention trials, three large studies 
demonstrated that neither a-tocopherol nor beta-carotene had preventive effects on lung 
cancer (68, 62, 63). In the 1990s, a comprehensive international chemoprevention trial 
was conducted in which smokers and ex-smokers were treated with �-carotene or 
retinoid. However, the �-Carotene and Retinol Efficacy Trial (CARET) and Alpha­
Tocopherol, �-Carotene {ATBC), showed that agents which effectively inhibit lung 
cancer growth in a preclinical model of hamster tracheo-bronchial organ cultures had the 
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opposite effect on human lung cancer. Five years into the trials, this study had to be 
discontinued due to a 46% increase in lung cancer mortality and a 26% increase in 
cardiovascular mortality in the groups receiving �-carotene and retinyl palmitate (62, 66). 
As cardiovascular function as well as the growth regulation of PAC are under beta­
adrenergic control, we hypothesized that �-carotene caused the dramatic increase of both 
diseases in this trial because it increases intracellular cAMP by inhibition of the enzyme 
phosphodiesterase (69). We further hypothesized that beta-carotene would have selective 
strong promoting effects on the growth of human pulmonary adenocarcinoma cells of 
Clara cell phenotype (NCI-H322) and their normal cell of origin (SAEC) via its 
stimulatory effects on cAMP. We have also included theophylline in our experiments 
because it has the potential to increase intracellular cAMP. 
Beta-carotene is a member of the carotenoid family that consists of over 600 
compounds found predominantly in fruits and vegetables and is converted by the 
mammalian organism to vitamin A. This molecule has been reported to have a number of 
actions, including important antioxidant activity due to its inhibition of radical initiated 
peroxidation in vitro (70-73). Original epidemiologic data showed a positive association 
between f3-carotene deficiency in the diet and increased risk of lung cancer (58, 59, 60, 72 
-75). On the other hand, clinical trials involving �-carotene supplementation revealed 
unfavorable effects (62-65, 56, 68, 70). Among the possible explanations for this effect 
inhibition of absorption of other nutrients by large doses of �-carotene and the 
autocatalytic pro-oxidant activity of �-carotene under high oxygen tension such as that 
occurring in the lungs of smokers were discussed (74-76). The ability of beta-carotene to 
increase intracellular accumulation of cAMP by inhibiting phosphodiesterase ( 69) has not 
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been considered to date as a cause for the observed lung cancer promoting effects. Also, 
it has been suggested that �-carotene increases mortality of lung cancer and 
cardiovascular diseases (73). However, chemoprevention of lung cancer is proving 
difficult and frustrating (77). In general, lung cancer chemoprevention trials have been 
disappointing. Several large-scale chemoprevention trials have been performed, including 
the European Organization for Research and Treatment of Cancer Head and Neck and 
Lung Cancer Cooperation Groups (EUROSCAN) Trials, the Physician Health Study, the 
Alpha-Tocopherol and Beta-Carotene trial (ATBC, CARET), which involved thousands 
of active smokers followed up for over 10  years. Unfortunately, none of those studies 
have yielded favorable results. 
Green Tea (GT) was discovered in the year of 2737 BC by the Chinese emperor 
Sheng Nung. The traditional use of tea began in China about 4 700 years ago and it was 
often used as medicine. In the 8th century, tea was introduced in Japan and in Europe, and 
then very rapidly became an important commercial product throughout the world. (78). 
Tea is the most ancient and widely consumed beverage in the world next to water, 
made from leaves of the Camellia sinensis species of the theaceae family (79). Fresh tea 
leaves are rich in flavanol monomers of the polyphenol family known as catechins. The 
predominant catechins found in tea are epicatechin (EC), epicatechin gallate (ECG), 
epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG). EGCG is the most 
potent and widely used catechin in tea (80). While some sources additionally contain 
gallo catechin (GC) all of the catechins are contained in green tea extract GTE that is 
widely used as a dietary supplement. Green tea constituents have been characterized as 
antioxidants that scavenge free radicals to protect normal cells. The antioxidant effect is 
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directly related to the combination of aromatic rings and hydroxyl groups that make up 
the structure and also a result of binding and neutralizing of free radicals by the hydroxyl 
groups (8 1 ). However, results of epidemiological studies on tea and cancer have been 
inconsistent; some show consumption of tea is protective, whereas others show it either 
has no relationship with cancer or even increases the risk of certain cancers (82). 
Lung cancer studies have shown an inverse effect with Okinawan tea, yet a 
tentatively increased risk was shown in another study (83, 84). Although human studies 
have their limitations, the research has warranted a further look into the effects of green 
tea and cancer (83). However, early studies focused on the effects of polyphenols and 
catechins in tea on cancer development, while recent studies have identified anti­
mutagenic, anti-proliferative, and anti-neoplastic effects of all tea fractions (85), 
suggesting that non-catechin components of tea contribute to the cancer modulating 
effects of tea. Theophylline which is also contained in tea has been given little attention 
by cancer researchers. This agent is a widely documented inhibitor of phosphodiesterase 
(85-88, 89) and increases intracellular cAMP via this mechanism. In the current projects 
experiments on NCI-H322 and SAEC have been performed to test the hypothesis that 
theophylline which is the main component of green tea, promotes growth-regulating 
signal transduction. 
The principal current use of theophylline began in the early 1 970s with reports 
demonstrating its efficacy as preventive medicine for chronic asthma (90) and by 1 980, 
theopyhlline had become a leading medication for asthma because of its bronchodilating 
effects (9 1 ). Theophylline in fact, has immunomodulatory (92), anti-inflammatory (93, 
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94, 42), and bronchoprotective effects that potentially contribute to its efficacy as a 
prophylactic antiasthma drug (95-97). 
III. Growth-Regulating Signaling Pathways Expressed in Lung 
Epithelia and Lung Cancer 
The epidermal growth factor receptor (EGFR) 
Generally, a signal is transmitted from the cell membrane to the nucleus through 
interaction of proteins, and conversion of those proteins from inactive to active status. 
This begins with the interaction of signals with the membrane receptors. This 
extracellular signal may include growth factors hormones, neurotransmitters, 
extracellular matrix, and stress signals. This interaction activates the receptor, which then 
catalyzes a series of reactions beginning with the activation of a secondary protein, often 
through cofactors such as ATP, GTP, cAMP, or cations. This protein often catalyzes the 
activation of the third protein, and this pattern continues in a cascade of reaction, usually 
involving cytoskeleton proteins like beta-catenin and APC, adapter proteins, kinases and 
phosphatases. The kinases can be either receptor, like the EGF receptor, or non receptor, 
like Src and Jak. This cascade culminates in the activation or deactivation of transcription 
factors, like c-myc, or other factors, and translocalization of these factors into the nucleus 
(89, 1 01, 103-106). 
Cell growth is regulated by several growth factors by activating intracellular 
signaling pathways after binding to high affinity tyrosine kinase receptors on the cell 
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surface. Among these, the mitogenic activated protein kinase (MAPK) pathway plays an 
important role in the transduction of mitogenic signals initiated by growth factors acting 
on a variety of cell surface receptors. MAP kinases are regulated through many protein 
phosphorylation cascades (89, 1 01 ,  1 03-1 06). 
Several stimulatory growth factors are found in lung cancers including, epidermal 
growth factor (EGFR), transforming growth factor alpha (TGFa), insulin growth factor-
1 /2 (IGF-1 /2), platelet derived growth factor-A/B (PDGF-A/B), fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor, (HGF), and 
mammary derived growth factor- I (MDGF-1 )  (98, 99). The epidermal growth factor 
receptor (EGFR) is a 170 KDa transmembrane receptor with tyrosine kinase activity, 
which has several ligands including EGF, amphiregulin (AR) and TGFa (98). EGF and 
EGFR are frequently over-expressed in lung cancers ( 117, 1 18). 
The EGFR signaling pathway demonstrates remarkable flexibility in mediating a 
host of signaling pathways that regulate various physiological and pathological processes. 
The EGFR belongs to the receptor tyrosine kinases (RTKs) family. RTKs have an 
intrinsic enzymatic activity in the cytoplasmic region that is directed against the receptor 
and downstream signaling molecules (100). The RTKs are involved in a range of cellular 
physiology including fertilization, proliferation, cell migration and apoptosis. 
Furthermore, they play an important role in cancer development ( 101 ). 
The EGFR is expressed in many cell types as well as regulates many cell 
functions ( 102, 1 03), and it has four closely related receptors called the EGFR family 
(erbB l ), erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4). 
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The Ras-mediated mitogen activated protein kinase (MAPK) cascade is one of the 
best characterized signaling pathways initiated by EGFR activation. The Ras- mediated 
EGFR-MAPK cascade is initiated when the growth factor Grb- 2 associated SOS (Ras 
guanine nucleotide exchange factor) is recruited to phosphotyrosine residues of activated 
EGFR. This association allows the exchange of GDP (inactive form of G-protein) to 
GTP, which is the active form of G-protein. This is followed by membrane recruitment 
and activation of the serine/threonine kinase Raf (MAPK kinase kinase), which in turn 
phosphorylates and activates MEK (MAPK kinase). The dual-specific MEK 
phosphorylates and activates the serin/ threonine mitogen activated protein kinases 
(MAPKs) ( 104 ). There is increasing evidence that MAP kinase can be activated by a 
variety of signals, including growth factors ( 1 05), phorbol esters ( 1 06) and calcium ion 
(Ca2l ( 1 07). 
In summary, the epidermal growth factor (EGF) pathway is found in many cancer 
cells. In this cascade, EGF binds to its receptor (EGFR) leading to the dimerization of the 
receptor. This leads to autophosphorylation of the receptor tyrosines, and recruitment of 
proteins to the receptors, which bind to the receptor via their SH2 domains. One such 
protein is Grb2-SOS. In tum, this protein activates Ras through conversion of GDP to 
GTP. Ras then activates Raf. Raf activates MEK which activates MAPK (ERK). MAPK 
activates factors such as SRF, ATF, c-fos, c-Jun, c-myc leading to gene expression and 
cell proliferation ( 1 04, 1 08, 1 09). 
Besides the classical Ras-mediated kinase cascade, various signaling molecules 
could also undergo phosphorylation and activation upon binding to the phosphotyrosine 
residues on activated EGFR. Activated Phospholipase C (PLC) hydrolyses membrane 
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bound phosphatidylinositol (PI) yielding diacylglycerol (DAG) and inositol phosphates 
( 1 1 0). Inositol phosphate regulates intracellular calcium, which together with DAG, 
activates protein kinase C (PKC). PKC causes potent activation of ERK through the 
direct phosphorylation and activation of Raf- 1 ( 1 1 1 , 1 1 2). 
Phosphatidylinositol 3-kinase (Pl 3K) binds to phosphorylated tyrosine residues of 
receptor tyrosine kinases (RTKs) ( 1 1 3). Phosphorylated inositol phospholipids 
(Phosphatidylinositols) are required for the membrane localization of phosphoinositide­
dependent kinase (PDK). PDK phosphorylates and activates protein kinase B (Akt), 
which is involved in cell proliferation and inhibition of apoptosis ( 1 14). Recently 
Akt/PKB was identified as a promoter of cancer cell invasion through increased motility 
and metalloproteinase production (1 1 4) .  The requirement of P1 3K for the induction of 
DNA synthesis in cells was demonstrated by Roche et al. 1 994 ( 1 1 5). Among the proteins 
that become phosphorylated and activated by EGFR is the Janus kinase 1 (JAK 1 )  and 
STAT to the nucleus for gene activation ( 1 1 6, 1 1 7). 
The epidermal growth factor receptor and lung cancer 
An autocrine growth loop is present when both receptor and its ligand are co­
expressed in a cell with self-regulated proliferation ( 1 1 8). EGFR has been implicated as a 
promoter of proliferation and progression of malignant cells via various autocrine growth 
pathways that have been associated with the pathogenesis of many cancers (1 19). 
Several studies have shown that EGFR plays a major role in the autocrine growth 
of human non-small cell lung cancer (NSCLC) ( 120). The family of NSCLC consists of 
adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and carcinoid (3 1 ). 
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Expression and overexpression of EGFR was found in a greater proportion of squamous 
and adenocarcinomas than in large cell or small cell carcinoma (120, 121). The co­
expression of transforming growth factor-a. (TGF-a.) and the EGFR exists in many lung 
cancer cell lines particularly in NSCLC (120, 50). TGF-a is the main and most important 
autocrine ligand in NSCLC tumor formation. Moreover, activation of point mutations of 
the Ras gene resulting in constitutively active mitogenic signals were observed in about 
30% of NSCLCs (122, 123, 124). 
Over-expression of EGFR is associated with reduced survival ( 121, 125, 126), 
metastasis (127), and resistance to chemotherapy (126-128). In lung cancer, many 
chemotherapeutic approaches have targeted the EGFR signaling pathway with 
encouraging preclinical results (131, 132). 
Signaling through G-Protein receptors 
G protein-coupled receptors (GPCRs) are among the largest family of cell surface 
receptors. They mediate signaling from a number of stimuli and ligands including peptide 
and glycoprotein hormones, neurotransmitters, phospholipids and photons. These 
receptors consist of an extracellular ligand binding domain, a seven transmembrane 
domain, and heterotrimeric G-proteins (133, 134). The heterotrimeric G-proteins consist 
of a, �' y subunits, which dissociate into active Ga-GTP and G�1-subunits after interaction 
with ligand-bound receptor. However, there are numerous Ga-proteins, the main classes 
of which are Gas , which activate adenylyl cyclase; the Gai , which inhibit adenylyl 
cyclase; and Gaq which activate phospholipase C. Beside the Ga subunits, the G�-subunit 
is also involved in regulating various effectors, including adenylyl cyclase, phospholipase 
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C and A2 isoforms, serine threonine kinases, and protein kinase C ( 1 34, 1 35). When an 
agonist binds to GPCRs, the bound GDP exchanges to GTP on the G-proteins leading to 
the dissociation of G-protein into active Ga-GTP and Gpy subunits. Once the agonist 
leaves the receptor, the subunits associate to each other again to form inactive form of G­
protein (GDP) bound state ( 1 36- 1 38). 
From events occurring at the cell membrane to make changes in gene 
transcription, the cyclic AMP ( cAMP)-dependent signaling pathway is a classic signaling 
pathway that has been well characterized. Once ligand (hormones, neurotransmitters, 
growth factors) bind to the specific receptors located in the plasma membranes, an 
allosteric change occurs, allowing it to bind to the G-protein. The G-protein becomes 
active and GTP binds to G-protein and GDP (inactive form of G-protein) will be 
released. Now the G-protein can move and transfer a message from the receptor to the 
catalytic subunit. The Gs protein then stimulates the activation of the enzyme adenylyl 
cyclase, which converts ATP via hydrolyzation to cAMP. cAMP acts as a second 
messenger to activate protein kinases which will phosphorylate other proteins such as 
protein kinase A(PKA). Activation of PK.A results in the downstream activation of either 
CREB or Erkl/2 and finally causes cellular response such as proliferation ( 1 39, 89). 
p -adrenergic signaling and cancer 
Beta-adrenergic receptors are members of the super family of seven­
transmembrane G-protein coupled receptors encoded by a gene on chromosome 5 (140). 
Beta-adrenergic receptors are classified into � 1 -, �2-, and �3-receptors ( 140, 1 4 1 ). In the 
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lungs, P 1 - and P2 receptors are widely distributed in epithelia, smooth muscle cells, and 
endothelial cells (142, 143). p3-receptors have not been identified in lung tissues but are 
abundant in adipose tissues. The functions of P-adrenergic receptors in �ndothelia, 
bronchial smooth muscle cells, vascular smooth muscle cells, cardiac muscle, and 
pulmonary macrophages has been well characterized. It is well established that beta­
adrenergic signal transduction pathway plays a key role in cardiovascular disease and 
asthma (144). It has also been shown that beta-adrenergic receptors regulate secretion of 
alveolar type II cells, bronchiolar Clara cells and Mucociliary clearance (142, 143). 
Elevation of cAMP influences cell physiology, including proliferation, survival, 
and differentiation, either stimulating or inhibiting the response depending on cell type 
and context. Conflicting effects reported for cAMP might result from differences in cell 
types, concentration, and localization of the cAMP dependent protein kinase (145). There 
are 9 isoforms of adenylyl cyclase enzyme and the tissue specific expression of the 
specific isoforms determines the relative amount of cAMP in response to stimuli (89). 
Moreover, the large number of possible combination of different G-protein subunits and 
effector molecules allows cells to respond in different ways (146). Phosphodiestrase 
degrades cAMP to 5'-adenosine monophosphate (5'-AMP) terminating the cAMP 
mediated effect of hormone stimulation. 
Cyclic AMP activates protein kinase A (PKA) which phosphorylates numerous 
proteins, with subsequent modulation of different cellular functions, including gene 
transcription. Gene transcription is mediated through the PKA-mediated activation of 
cAMP-responsive transcription factors including cAMP response element binding protein 
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(CREB), cAMP response element modulator (CREM), and activating transcription 
factor- I (ATF- 1 )  (89). 
The growth of some types of cancer is stimulated by �-adrenergic signaling. This 
signaling pathway enhances the growth of human lung adenocarcinoma cell lines (39, 
43), pancreas (147) or breast ( 148). Park et al, 1 995 (39) initially demonstrated the 
mitogenic role of �-adrenergic signal transduction in human PAC of the Clara cell 
phenotype. This work showed the importance of �-adrenergic stimulators/cAMP in the 
proliferation of human cancer cell lines derived from peripheral pulmonary 
adenocarcinoma with features of Clara cells (NCI-H322) and their normal cell of origin 
immortalized small airway epithelium cells. 
Finally, current data imply that PAC of Clara cell phenotype and small airway 
epithelia cells with characteristics of Clara cells respond to elevated cAMP levels in the 
same manner. This is likely to have important clinical and epidemiological implications 
since beta-adrenergic stimulators are active ingredients of drug formulations that are 
widely used in the management of chronic respiratory diseases and dietary supplements 
for weight control. 
Figure 1 1 shows that beta-adrenergic receptors on pulmonary epithelial cells 
activates GTP-binding proteins (G-proteins) coupled to receptor signaling, resulting in 
the activation of adenylyl cyclase and cyclic AMP ( cAMP), followed by activation of 
protein kinase A (PKA) depending on the cell type, PKA can activate the transcription 
factors cAMP response element binding protein (CREB), cAMP response element 
modulator (CREM), activating transcription factor- I (ATF- 1), activator protein 1 (APl) 
1 See all figures and figure legends in Appendix. 
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or nuclear factor KB (NF- KB) which all regulate cell proliferation. Alternatively, PK.A 
can activate the small G-protein RAP-1, leading to the activation of serine/threonine 
kinase B-RAF, followed by activation of the mitogen-activated protein kinase (MAPK) 
cascade and transcriptional activation of proliferation. PK.A can also activate 
phospholipase-A 2 (PLA2) to release arachidonic acid (AA) from cell membrane 
phospholipids. AA itself, as well as its metabolites such as prostaglandins and 
leukotrienes, can also activate. 
In Figure 2 the flow-chart represents a simplified version of beta-adrenergic 
signaling in NCI-H322 and SAEC cells that has been focus of this proj ect. OTP-binding 
proteins (G-proteins) coupled to receptor signaling, results in the activation of adenylyl 
cyclase and cyclic AMP (cAMP), followed by activation of protein kinase A (PK.A). In 
our project, we hypothesized that PK.A can activate the transcription factor cAMP 
response element binding protein (CREB). Alternatively, PK.A can activate the small G­
protein RAP-1, leading to the activation of serine/threonine kinase B-RAF, followed by 
activation of the mitogen-activated protein kinase (MAPK) cascade, all of which may 
lead to the activation of human cancer cell lines derived from peripheral adenocarcinoma 
with features of Clara cells (NCI-H322) and their normal cells of origin (SAEC) and 
transcriptional activation of proliferation. Also, depending on cell type, ERK 1 /2 may 
activate CREB or CREB may activate ERK.1/2. 
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Figure 1 .  cAMP-dependent signal transduction in response to �-adrenergic receptor 
stimulation. Binding of agonists to the receptor will activate the enzyme adenylyl cyclase, 
leading to the activation of the second messenger cAMP which in turn phosphorylates 
other downstream proteins such as its associated protein kinase A (PKA). In turn, PKA 
may phosphorylate the transcription factors CREB, CREM, ATF- 1 ,  or NF-kB, or 
activation of PK.A may phosphorylate the MAPK cascade through the activation of Rap-I 
and b-Raf or it may activate Phospholipase A2 which then leads to release of AA. 
However, the activation of the transcription factors in all three different ways will cause 
cellular response such as cell proliferation. 
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Figure 2. Flow-chart represents a simplified version of �-adrenergic signaling in NCI­
H322 and SAEC cells that has been focus of this project. cAMP-mediated signal 
transduction pathway in response to �-adrenergic receptor stimulation. Once stimuli bind 
to the receptor in the cell membrane, the enzyme adeny ly cyclase will be activated via 
ATP hydrolyze, which then will activate the second messenger cAMP. cAMP will 
activate protein kinase A (PKA), which in turn will activate either CREB or Erkl /2 
which either one will finally causes cell proliferation. 
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PART III : 
Growth stimulation of human pulmonary adenocarcinoma 
cells and small airway epithelial cells by P-carotene via 
activation of cAMP, PKA, CREB and ERKl/2 
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Part III 
Brief explanatory statement 
This chapter is a lightly revised version of a manuscript by the same name that has 
recently been submitted to the journal "Cancer Research". November 4, 2004 . 
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My use of "we" in this chapter refers to my co-authors and myself. My primary 
contributions to this paper include ( 1) selection of the topic, (2) development of assay 
conditions suitable to test the hypothesis that �-carotene stimulates the growth of 
pulmonary adenocarcinoma cells and their normal cells of origin, (3) conduction of 
cAMP assays, ( 4) conduction of PKA activation assays, ( 5) conduction of Western blots, 
( 6) conduction of MTT assays, (7) analysis and interpretation of all data, (8) statistical 
analysis of all data, (9) photographic and graphic documentation of results, (10) 
conduction of comprehensive literature reviews, (11) writing of the manuscript (with 
some editorial assistance by Dr. Schuller). 
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Introduction 
Lung cancer is the leading cause of cancer deaths in industrialized countries { l -3). 
Among the four major types of lung cancer recognized by the WHO classification 
(adenocarcinoma, small cell carcinoma, squamous cell carcinoma, large cell carcinoma) 
pulmonary adenocarcinoma (PAC) predominates today, accounting for about 60% of all 
lung cancer cases (2, 4, 5). Smoking is a well documented risk factor for all types of lung 
cancer ( 6, 7) while a high fat diet constitutes an additional risk factor for PAC (8- 10). 
Human PAC may be derived from bronchiolar Clara cells or from alveolar type II cells. 
Immunohistochemistry is primarily used to identify cell lineage of this cancer type by 
using antibodies to the Clara cell-specific CC 1 0  protein and the alveolar type II cell­
specific surfactant. Using this technique, PAC of Clara cell lineage has been reported to 
account for about 50% of PAC cases (1 1 ). By contrast, electron microscopic 
investigations have identified 90% of PAC as being derived from Clara cells ( 12) .  
Recent reports have shown that exposure to cigarette smoke or the tobacco-specific 
carcinogenic nitrosamine 4 (methylnitrosamino )-1 -(3-pyridyl)-1 -butanone (NNK) down­
regulate the expression of the Clara cell-specific CCl 0  protein in human and animal 
lungs (1 3). These findings suggest that identification of PAC cell lineage by 
immunohistochemistry may result in significant numbers of false negative 
immunoreactions to the CC 1 0  antibody because of down-regulated CC 1 0  in smokers. 
Accordingly, a higher proportion of PA Cs are likely of Clara cell lineage than is 
generally accepted in the literature. 
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Studies in our laboratory have shown that the in vitro growth of human lung 
cancer cell lines derive from PAC of Clara cell lineage are regulated by P-adrenergic 
receptors and that the tobacco-specific carcinogenic nitrosamine 4-(methylnitrosamino )­
(3-pyridyl)- 1 butanone (NNK) acts as an agonist for this receptor family ( 14). NNK as 
well as a stimulator of the classic downstream effector of P-adrenergic receptors, cAMP, 
significantly stimulated DNA synthesis of these cells in vitro ( 14, 1 5). In support of these 
data, studies in a hamster model of NNK-induced Clara cell-derived PAC have shown 
that P-adrenergic agonists ( 16) and the phospodiesterase inhibitor theophylline ( 17) , 
which causes intracellular accumulation of cAMP, each significantly promoted the 
development of this cancer type . 
A multinational chemoprevention trial with P-carotene and retinoids (P-carotene 
and retinoid efficacy "CARET" trial) was conducted in the 1990s in populations at risk 
for the development of lung cancer because of previous or current exposure to smoking 
or asbestos ( 1 8, 1 9). This trial was based on preclinical studies that had shown in vivo 
and in vitro inhibition of chemically induced carcinogenesis in the upper airways of 
hamsters by the pro-vitamin P-carotene or by synthetic vitamin A analogues of the 
retinoid family (20-24). In addition, a strong promotion of diethylnitrosamine-induced 
tracheobronchial carcinoma by vitamin A-deficiency was reported in hamsters (25). The 
trial had to be discontinued after 5 years due to a 28% increase in lung cancer incidence 
and mortality (46%) and a 26% increase in cardiovascular mortality ( 1 9). Conclusive 
explanations for this disconcerting result have not been provided to date. 
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It is well established that cardiovascular function is under P-adrenergic control 
and J3-blockers are widely used for the clinical management of hypertension and heart 
disease (26). In light of our recent in vitro and in vivo findings on the P-adrenergic 
regulation of PAC, we therefore hypothesized that the chemopreventive agents used in 
the CARET trial may have promoted the development of PAC via stimulation of a 
signaling component of its P-adrenergic regulatory pathway. An extensive literature 
search revealed that P-carotene has been shown to increase intracellular cAMP in 
neuroblastoma cells (27). Our current experiments have therefore focused on the effects 
of P-carotene on cAMP and its associated downstream pathways as potential mediators of 
a stimulating effect on the proliferation of a human Clara cell-derived PAC cell line and 
its putative cell of origin (immortalized human small airway epithelial cells). Our data 
provide strong evidence in support of the hypothesis that P-carotene stimulates the 
growth of these cells via an increase in intracellular cAMP, activation of protein kinase 
A, activation of the cAMP response element (CREB) and activation of the extracellular 
signal-regulated kinases (ERK 1 /2 ). 
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Materials and Methods 
Cell lines and tissue culture 
The human PAC cell line with characteristics of Clara cells, NCI-H322, was 
purchased from the Center for Applied Microbiology and Research (ECACC, Salisbury, 
Wiltshire, UK). NCI-H322 cells were maintained in RPMI-1640 medium containing 
1 0mM HEPES; lmM sodium pyruvate; 2mM L-glutamine; 4500 mg glucose/L; and 
1500 mg sodium bicarbonate/L), supplemented with 10% fetal bovine serum (FBS) but 
without supplement of antibiotics. The Simian virus 40 (SV40)-immortalized human 
peripheral airway cell line HPL 1 D (28), referred to in this publication as small airway 
epithelial cells SAEC, was provided to us by Dr. Takashi Takahashi (Aichi Cancer 
Center Research Institute, Nagoya University, Chikusa-ku, Nagoya 464, Japan). These 
cells were maintained in F-12 (HAM) medium buffered with 1 5mM HEPES (pH 7 .3; 
Gibco Invitrogen-Life Technologies, Carlsbad, CA) and supplemented with 5µg/ml 
bovine insulin, 5µg/ml human transferrin, 10·7 M hydrocortisone, 2 x10· 10 M triiodo­
thyronine (Cambrex Bio Science Walkersville, Inc, Walkersville, MD) and 1 % fetal calf 
serum (FCS; ATCC, Manassas, VA). No antibiotic was added. The SV40/adinovirus/12 
hybrid virus immortalized human bronchial epithelial cell line BEAS-2B was obtained 
from the American Type Culture Collection (Rockville, MD). These cells were 
maintained in bronchial epithelial cell basal medium (BEBM) supplemented with 2ml 
BPE, 0.5ml insulin, bovine (5mg/ml), 0.5ml HC, 0.5 ml retinoic acid, 0.5ml transferrin, 
0.5ml T3, 0.5ml epinephrine, 0.5ml HEGF (Cambrex Bioscience Walkersville, MD) 
and without supplement of antibiotics. 
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cAMP Immunoassay 
The level of cAMP in cell lysates was determined with a direct cyclic AMP 
Correlate- EIA TM kit (Assay Design, Ins. ,  Ann Arbor, Ml), according to the instructions 
by the manufacturer. Briefly, in this competitive binding assay the cyclic AMP present in 
a sample competes with a fixed amount of alkaline phosphatase-labeled cyclic AMP for 
sites on a rabbit poly clonal antibody to cyclic AMP. During the incubation, the 
polyclonal antibody is bound to a goat anti-rabbit antibody coated on the microplate . 
Following a wash to remove excess conjugate and unbound sample, a substrate solution, 
p-nitrophenyl phosphate, is added to the wells to determine the bound enzyme activity. 
The color development is stopped with a solution of trisodium phosphate after an hour of 
incubation and the absorbance is read at 405 nm. The intensity of the color is inversely 
proportional to the concentration of cyclic AMP in the sample. 
NCI H322 cells or SAECs were seeded into 6-well plates (Falcon, Franklin Lakes, 
NJ, USA) at 4 x 1 05 cells/ well in their individual media as specified above and 
maintained in an environment of 3 7°C, 5% CO2 until they had reached 65-70 confluence . 
The media were then removed and replaced by low serum medium (0 . 1% FEBS) for 
NCI-H322 cells or basal F- 12  medium (0.05% FBS) without additives for SAECs to 
starve the cells for 24 hours. The cells were then washed twice with lX PBS and 
preincubated with fresh RPMI- 1640 medium (0. 1% FBS) for NCI-H322 cells or F- 12 
medium (0.05% FBS) for SAECs containing 3-isobutyl- 1 -methylxanthine ( lmM) for 30 
minutes. Following removal of this preincubation mix, the cells were incubated for 1 0  or 
30 minutes with P-carotene type 1 (20 nM, Sigma, Louis, MO, USA) in fresh media 
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containing lmM IBMX in an atmosphere of 37°C ,  5% CO2. Following 3 washes with 
sterile distilled water, the cells were then incubated with 600 µl of O. lM  HCL for 20-30 
minutes and scraped off the well surfaces with a plastic scraper (Fisher Scientific, GA, 
USA). The cell lysates were collected into 1 .5ml Eppendorf tubes and stored in ice. 
Following sonication of the cell lysates at 40 rpm for 1 0  seconds (Fisher Sonic 
Dismembrator. Model 300), the samples were immediately analyzed using the standard 
non-acetylated version of the cAMP enzyme immunoassay kit, according to the 
manufacturer's instructions. Each experiment was repeated three times. Data are 
expressed as mean values and standard errors of three independent experiments, each 
conducted with triplicate samples per treatment group. Statistical analysis of data was by 
one-way ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t­
test. Following statistical analysis, data were normalized with controls set as 1 00% for 
documentation as column graphs. 
PKA activation assay 
Following incubation of cells with P-carotene (20 nM) for 5 minutes to 2 hours 
as specified in the figure legends, PKA activity was assayed in cell lysates using a Pep 
Tag assay for non-radioactive detection of activated PKA (Promega Corperation, 
Madison, WI, USA), following the instruction of the manufacturer. Tubes containing 
the catalytic subunit of PKA (provided with the kit) served as positive controls.This 
assay utilizes fluorescent substrate for PKA that changes the peptide's  net charge upon 
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phosphorylation of PKA, thus allowing the phopsorylated peptide to migrate to the 
positive electrode (+), while the non-phosphorylated peptide migrates to the negative 
electrode (- ). All samples were kept on ice. At time zero, the samples were removed 
from the ice and incubated in a water bath at 30°C for 1 minute. A 1-10 µI aliquot from 
each sample was added to the reaction cocktail (5µ1 PEP Tag PKA reaction 5X buffer, 5 
µI Pep Tag A 1 peptide, 5 µI PKA activator 5X solution, 1 µI peptide protection 
solution) and incubated for 30 minutes at room temperature. The reaction was stopped 
by placing all samples into a boiling water bath or at 95°C in a heating block for 10 
minutes. All samples were stored at -20°C in the dark until loading into 0.8% agarose 
gels (GIBCOBRL, Grand Island, N.Y, USA; 100 V for 15-18 minutes) in the presence 
of 50mM Tris-HCL (pH 8) (Fisher Biotech, Fair Lawn, New Jersey), using a Gel XL 
Plus Electrophoresis System (Labnet International, Inc., Woodbridge, NJ), following 
the addition of 1 µI of 80% glycerol per sample. An electronic transilluminator camera 
(Ultra Lum, Inc., Paramaount, CA) was used to view and capture the images for 
densitometric analysis (Scion software for image quantitation, NIH). Each experiment 
was conducted independently under identical conditions three times with similar results. 
Data are expressed as mean values and standard errors of three independent 
experiments, each conducted with triplicate samples per treatment group. Statistical 
analysis of data was by one-way ANOVA, Tukey-Krarper multiple comparison test and 
two-tailed unpaired t-test. Following statistical analysis, data were normalized with 
controls set as 100% for documentation as column graphs. 
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Western blotting of proteins and phosporylated proteins 
To assess the effects of �-carotene on the expression and phosphorylation of 
the mitogen activated protein kinases ERK.1/2 or the cAMP response element binding 
protein CREB, 500,000 NCI-H322 or SAEC cells were seeded into culture vessels ( 100 
cm2) containing their respective growth media. When the cells had reached 60-65% 
confluence, they were rinsed one time with lX PBS and serum-starved for 24 hours. 
Following removal of the media and replacement with fresh low-serum media, �­
carotene (20 nM) was added to the culture vessels and cells were incubated from 5 
minutes to 2 hours as detailed in the figure legends. Cells exposed to the �-carotene 
vehicle ( dimethylsulfoxide) served as controls. The cultured cells then were washed 
once with cold PBS, and were mixed with an appropriate volume of cell lysis buffer 
containing 20mM Tris-base, 200mM NaCL, lM Sodium Floride, 0.5M EDTA, l OOmM 
Na3 V04, l OOmM PMSF, 1µ1/ml of pepstatin A, 1 µ1/ml of leupeptin, 1 µ1 of aprotinin 
(protease inhibitor, Sigma-Aldrich, St. Louis, MO) and 0.25% NP-40 (Calbiochem, La 
Jolla, CA). The cells were reincubated with lysis buffer at 4°C for 20-30 minutes in the 
refrigerator and were then scraped off. The cell lysates were collected into 1 .5ml 
Eppendorf tubes and kept on ice. The lysates were vortexed for 1 0  minutes and stored in 
liquid nitrogen for 1 minute then thawed for 2 cycles. The lysates were clarified by 
centrifugation at 1 5 ,000 x g for 30 minutes at 4°C and the protein concentration was 
determined using a BCA protein assay kit (Pierce, Rockford, IL). Samples were boiled 
with 4X SDS sample protein loading buffer containing 200mM Tris-Hcl (pH 6.8), 
l OOmM DTT, 8% SDS, 0.5 -0. 1 % bromophenol blue, and 40% glycerol (Sigma-
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Aldrich, St. Louis, MO). Prestained protein marker, broad range (New England Biolabs, 
Inc., Beverly, MA) and 20-30 µg of protein samples were loaded/ lane and running 
buffer for protein sample separation (Bio-Rad, Alfred Nobel Drive, Hercules, CA). This 
gel was transferred in methanol (Fisher Scientific), and distilled water at 1 OOV for 1 
hour then washed one time with lX TBST (200mM Tris-HCL and 1 .5M NACL per 
liter) and 0.05% tween-20 (Sigma). Membranes were blocked in 1 0ml of 5% non-fat 
dry milk (Kroger) in lX TBST for 1 hour. Membranes were then incubated over night 
at 4°C with primary antibodies (rabbit antibody for total ERKl/2, rabbit Thr202/Tyr204 
for phospho-Erkl /2, each at a 1 :  1 000 dilution; Cell Signaling Technology, Beverly, 
MA). As a control for equal loading of the lanes, a monoclonal anti-actin clone (Ac-74, 
mouse source, Sigma-Aldrich, St. Louis, MO) was used at a 1 :  1 000 dilution. At the end 
of the incubation period, five five-minute washes were done with lX TBST. 
Membranes were further incubated with the secondary antibodies in 1 0ml of 5% non-fat 
dry milk in TBST at room temperature for one hour. The secondary antibodies, 
Alexflour 680 goat-anti-rabbit IgG (Probes Eugene, Oregon, USA) and IRDye 800 
conjugated affinity purified anti-mouse IgG (Rockland Immunochemicals, Inc., 
Gilbertsville, PA) were used at 1 :2500 dilution and 1 :5000 dilution respectively. 
Membranes were then rinsed five times five-minutes each with lX TBST. An Odyssey 
scanner and software (Lincoln, Nebraska, USA) were used for membrane scanning and 
visualization of bands. The same cell lysates and methods were used to assess the 
effects of �-carotene on CREB and phosphorylated CREB. A rabbit polyclonal CREB 
antibody (Cell Signaling Technology, Beverly, MA) was used as a primary antibody for 
total CREB ( dilution 1 :  1 000), while a monoclonal mouse antibody that recognizes 
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SER33 of phosphorylated CREB (Cell Signaling Technology, Beverly, MA) was used 
to probe for the activated form of CREB ( dilution 1 :  1000). Each Western blot was 
repeated three times under identical conditions and yielded similar data. Data are 
expressed as mean values and standard errors of three independent experiments, each 
conducted with triplicate samples per treatment group. Statistical analysis of data was 
by one-way ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired 
t-test. Following statistical analysis, data were normalized with controls set as 100% for 
documentation as column graphs. 
MTT assay for the assessment of cell numbers 
The effects of �-carotene on cell proliferation were assessed by the colorimetric 
3-(4, 5-dimethyle thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (2) 
(Sigma-Aldrich Co., St. Louis, MO, USA. Briefly, the MTT test is based on the NADH­
dependent enzymatic reduction of the tetrazolium salt MTT [3-( 4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-tetrazoliumbromide] in metabolically active cells but not in dead cells. 
Cells were seeded into 6-well tissue culture plates (Falcon, Franklin Lakes, NJ, USA) at 
a density of 50,000 cells per well for NCI-H322, and 50,000 cells per well for SAEC 
and BEAS-2B cells. The cells were left to grow in complete media at 37°C with 5% 
CO2 for 5 hours to attach. The cells were then switched to fresh low serum media and 
�-carotene was added at the concentrations specified in the figure legends and incubated 
for 72 hours. Pre-icubation of cells with inhibitors of adenylyl cyclase (SQ22536, 500 
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nM) or ofERKl/2 (PD98059, 1 µM) for assays documented in the inset of Figure 5 was 
for 10 minutes. Fresh low serum medium of each cell line and fresh treatment were 
added every other day. After treatment for 68 hours 50µ1 of [3-(4, 5-dimethyl thiazol-2-
yl)-2, 5-diphenyl tetrazolium bromide (0.5mg/ml) was dissolved in RPMI-1640 with L­
glutamine and phenol-free medium (Gibco Invitrogen Corporation, Grand Island, N.Y, 
USA)], added to the medium and incubated at 37°C in the incubator for another 2-3, 
allowing for the metabolic conversion of the MTT substrate to blue formazan. The 
media were then discarded and 550 µl of Isopropanol (2-propanol UV cutoff 205 nm, 
Fisher Scientific, GA, USA) was added to the wells. Absorbances at 570 nm and 630 
nm in each well were measured on a micro-ELISA reader. Data are expressed as mean 
values and standard errors of three independent experiments, each conducted with four 
samples per treatment group. Statistical analysis of data was by one-way ANOV A, 
Tu.key-Kramer multiple comparison test and two-tailed unpaired t-test. Following 
statistical analysis, data were normalized with controls set as 100% for documentation 
as column graphs. Data in the inset of Figure 5 that illustrates the effects of an adenylate 
cyclase inhibitor or an inhibitor of MEK on the stimulation of cell proliferation by P­
carotene were normalized with P-carotene-stimulated cells set at 100%. 
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Results 
We have previously shown that the proliferation of human PAC cells of Clara cell 
lineage in vitro and the development of this cancer type in NNK-treated hamsters is under 
P-adrenergic control ( 14-17). Moreover, our recent immunohistochemical studies have 
documented selective over-expression of PKA, phosporylated CREB and phosphorylated 
ERK.1/2 in the NNK-induced PACs (29). The activation of cAMP, PKA and CREB are 
classic events downstream of P-adrenergic receptor stimulation in many cell types 
unrelated to cancer (30-32). Similarly, activation of ERKl/2 has been reported as an 
effector of CREB or PKA in some cells (33-35). Taken together, our published data 
therefore point to an important role of cAMP, PKA, CREB and ERK.1/2 in the growth 
regulation of PAC of Clara cell linage in humans and in the hamster model. In an effort to 
understand the reasons for the unfortunate outcome of the CARET trial, we therefore 
tested the hypothesis that P-carotene may stimulate one or several components of this 
regulatory pathway. 
Exposure of the putative cells of origin of pulmonary adenocaricnoma, SAECs, to 
P-carotene (20 nM) caused a significant and time-dependent increase in intracellular 
cAMP as assessed by immunoassay (Figure 1 ). This response peaked after 10 minutes of 
exposure with a 1.6-fold increase. The response of the human PAC cell line NCI-H322 to 
an identical exposure of P-carotene was even more pronounced with a 2.5-fold increase 
of intracellular cAMP after 10 minutes of exposure (Figure 1 ). The observed stimulation 
of cAMP was reproducible as assessed by three independent experiments that yielded 
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similar results, each with three samples per treatment group. Statistical evaluation of the 
data by one-way ANOVA, Tukey-Kramer multiple comparison test and paired two-tailed 
t-test established significant differences between control and treatment groups as 
specified in the figure legends. 
Assessment of PK.A activation by a non-radioactive kit that measures the 
migration of the phosphorylated peptide to the positive electrode(+), while the non­
phosphorylated peptide migrates to the negative electrode (-), revealed a time-dependent 
increase in activated PK.A of SAECs exposed to J3-carotene (20 nM; Figure 2) with a 
maximum 2.6-fold increase at the 1 hour time interval (Figure 2). Similarly, the human 
PAC cell line NCI-H322 responded to 20 nM of J3-carotene with a time-dependent 
increase of PK.A activity that peaked at a 1 .6-fold increase (Figures 2a, b ). In both cell 
systems, the observed increase in PK.A activity was highly significant (p< 0.001 by one 
way ANOVA, Tukey-Kramer multiple comparison test and unpaired, two-tailed t-test 
from triplicate samples per treatment group of three independent experiments). 
The effects of J3-carotene (20 nM) on expression levels of the transcription factor 
CREB and its phosphorylated form were assessed by Western blot analysis (Figure 3). 
SAECs demonstrated a time-dependent increase in p-CREB protein with the highest level 
(4.7-fold increase) observed after 120 minutes of exposure (Figure 3). NCI-H322 cells 
were even more responsive to J3-carotene with a 4.8-fold increase in p-CREB observed 
after 5 minutes of exposure and peak values of 8.7-fold after 1 hour (Figure 3) In neither 
cell line did exposure to J3-carotene increase the levels of unphosphorylated CREB 
protein (Figure 3 ). The observed increases in p-CREB expression were highly significant 
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in both cell systems at all time intervals tested (p<0.00 1 by one way ANOVA, Tukey­
Kramer multiple comparison test and two-tailed unpaired t-test from mean values and 
standard errors of densitometric values from three independent experiments conducted 
under identical conditions, each with triplicate samples). 
The effects of �-carotene (20 nM) on the mitogen-activated kinases ERK.1/2 and 
their phosphorylated forms were also assessed by Western blotting. As exemplified in 
Figure 4, p-ERK.1/2 was significantly increased in SAECs at all time intervals tested with 
a 2.5-fold increase as early as 5 minutes after exposure to �-carotene and a peak value of 
4.6-fold at the 30 minute time interval (Figure 4). The response of the cancer cell line 
NCI-H322 to �-carotene was even more pronounced with a 4.8-fold increase in p­
ERK.1/2 expression after 5 minutes of exposure to �-carotene and a peak level of 7.8-fold 
at the 1 hour time interval (Figure 4). The observed increases in p-ERK.1/2 in both cell 
lines cells were highly significant at all time intervals tested (p<0.00 1 )  by one-way 
ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test from 
densitometric values of three independent experiments conducted under identical 
conditions, each with triplicate samples. Beta-carotene did not increase the expression of 
unphosphorylated ERK.1/2 protein in either cell system at any of the time intervals tested. 
The potential role of the observed changes in cAMP, PKA, and phosporylated 
proteins on cell proliferation was assessed by MIT assays. In our published studies on 
the growth-stimulating effects of �-adrenergic agonists and cAMP on NCI-H322 cells we 
used [3H]-thymidine incorporation assays that monitor DNA synthesis ( 14, 1 5). Because 
the MTT assay monitors numbers of viable cells which can be influenced by both, cell 
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proliferation and apoptosis, the results of the MTT assays were verified by [3H]thimidine 
incorporation assay with controls versus three concentrations ( 1 pM, 10 pM, 100 pM) of 
�-carotene (data not shown). We tested the effects of �-carotene on cell numbers in the 
MTT assay after 24, 48 or 72 hours of incubation. While the stimulating effects of �­
carotene were highly significant at all time intervals tested, the responses after 72 hours 
of exposure were the most dramatic and are therefore illustrated in Figure 5. Our data 
show that �-carotene caused a dramatic increase in the numbers of SAECs at all 
concentrations, an effect that peaked with a 13-fold increase after incubation with a 10 
pM concentration. Similarly, the cancer cells NCI-H322 were highly responsive to the 
growth-stimulating effects of �-carotene, an effect that peaked with a 12.3-fold increase 
at a 100 pM concentration of �-carotene (Figure 5). The stimulatory effects of �-carotene 
on cell proliferation in both cell systems were highly significant (p< 0.001) by one way 
ANOVA, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test. Pre­
incubation of the cells for 10 minutes with the adenylyl cyclase inhibitor SQ2536 (500 
nM) reduced the stimulating effects of �-carotene (20 nM) in SAECs and NCI-H322 cells 
to 27 and 32%, respectively (with fully �-carotene-stimulated cells set at 100%; Figure 5, 
inset). On the other hand, pre-incubation for 10 minutes with the MEK inhibitor 
PD98059 (10 µM) completely blocked the response of SAECs to �-carotene while 
reducing the response of NCI-H322 cells to 28% (Figure 5, inset). These data support our 
interpretation that the observed stimulating effects of �-carotene on the proliferation of 
SAECs and NCI-H322 cells was mediated by c-AMP-dependent signaling and activation 
of ERK.1/2. 
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Because the preclinical studies leading to the CARET trial had emphasized 
inhibiting effect of �-carotene on the development of chemically induced tumors derived 
from the upper airways of laboratory animals, we assessed the effects of �-carotene on 
immortalized human large airway epithelial cells (BEAS-2B) by MTT assay. In support 
of the original reports in hamster models, our data show a concentration-dependent 
decrease in cell number when BEAS-2B cells were exposed for 72 hours to �-carotene 
(Figure 6). The growth-inhibiting effects of �-carotene on these cells was highly 
significant (p< 0.001 by one way ANOVA, Tukey-Kramer multiple comparison test and 




The pro-vitamin �-carotene is converted in the mammalian organism to vitamin 
A. The majority of functions of vitamin A are carried out by its metabolite, retinoic acid 
(36), a transcriptional activator operating primarily through members of the nuclear 
receptor family of transcription factors (37). Synthetic retinoids continue to be widely 
studied as potential preventive and/or therapeutic agents for a variety of cancers (38-42) 
or disorders of the nervous system such as Parkinson's disease, motoneuron disease and 
Huntington's disease (37). In addition to the original preclinical studies on the prevention 
of cancer development from epithelia of the upper airways (20, 43-45), current research 
primarily concentrates on the use of retinoids for the prevention and/or therapy of head 
and neck cancer ( 40) or leukemia ( 41 ,  42). It remains undisputed that �-carotene and 
retinoids do have beneficial effects via inhibition of cell proliferation and/or stimulation 
of apoptosis in cancers of those cell lineages. In fact our MTT assay with the human large 
airway epithelial cells BEAS-2B confirm that. However, our data also provide 
compelling evidence for cell type-specific growth-stimulating effects of �-carotene on 
human PAC cells and their normal cells of origin (SAECs) via increase in intracellular 
cAMP, activation of PKA as well as phosphorylation of CREB and ERKl/2. In light of 
the prevalence of PAC, these novel and hitherto unknown mechanisms of action of �­
carotene should be considered as key factors responsible for the unfortunate outcome of 
the CARET trial. This interpretation gains strong support from the fact that both, lung 
cancer and cardiovascular deaths were significantly increased in the CARET trial ( 1 9). 
65 
As we have previously pointed out, PAC and cardiovascular disease not only share the 
same risk factors (smoking and high-fat diet) but they are also both regulated by P­
adrenergic receptor-initiated and cAMP-mediated signal transduction pathways ( 46). 
While it is far from understood which cellular mechanisms caused the increase in 
intracellular cAMP in response to P-carotene in our experiments, a similar effect of this 
pro-vitamin has been reported in neuroblastoma cells (27). It has also been shown that 
exposure of myeloid leukemia cells to a phosphodiesterase inhibitor that increased 
intracellular cAMP and activated PKA potentiated the cytodifferentiating action of 
retinoids (41). The dramatic increase in activated PKA, CREB and ERK.1/2 observed m 
SAECs and PAC cells exposed to P-carotene in our experiments is particularly intriguing. 
While phophorylation of ERK.1/2 is a key event downstream of numerous signaling 
pathways in many types of cancer (47-52), a potential growth-stimulating role of PKA 
and its downstream transcription factor CREB in cancer cells has been given little 
attention. To our knowledge, activation of PKA/CREB has only been implicated in the 
development of endocrine tumors (31 ). On the other hand, recent immunohistochemical 
studies conducted by us in NNK-induced PACs in hamsters have shown a strong and 
selective over-expression of PKA, phosphory lated CREB and phosphory lated ERK 1 /2 in 
the tumor tissue (29). Further studies are clearly needed to address the role of the 
cAMP/PKA/CREB pathway and its potential cross-talk with other signaling pathways in 
human PAC. 
The growth-stimulating effects of P-carotene observed in SAECs and PAC cells 
are in accord with published data that have documented a stimulation of cell proliferation 
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of human PAC cells in vitro in response to agents that increase intracellular cAMP (14, 
15). A cancer promoting effect of agents that increase intracellular cAMP has also been 
documented in a hamster model of PAC induced by the tobacco-specific carcinogen 
NNK (16, 17). By contrast, such agents inhibited the growth of human PAC cells of 
alveolar type II cell lineage (15) or human small cell lung cancer cells (53) and 
demonstrated significant cancer preventive effects in a hamster model of NNK-induced 
neuroendocrine lung tumors (17). 
Collectively, our current data and published evidence emphasize the fact that 
identical pathways can have very different functions in different cell types and in cancers 
of different cell lineages. Strategies that target regulatory signal transduction pathways 
for the prevention and therapy of cancer have to carefully consider this. Unless suitable 
diagnostic tools are developed that identify which signaling pathway is hyperactive in 
individual patients, clinical trials aimed at modulating signal transduction will continue to 
yield disappointing results. 
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Summary 
A multinational chemoprevention trial with B-carotene and retinoids (B-carotene 
and retinoid efficacy "CARET" trial) was conducted in the 1 990s in populations at risk 
for the development of lung cancer because of previous or current exposure to smoking 
or asbestos. The trial had to be discontinued after 5 years due to a 28% increase in lung 
cancer incidence and mortality ( 46%) and a 26% increase in cardiovascular mortality. 
The current experiments represent a first step towards unraveling the reasons for this 
disappointing outcome. 
Using a cell line derived from a human pulmonary adenocarcinoma of Clara cell 
lineage and immortalized human small airway epithelial cells; our data show that low 
concentrations of B-carotene that can be realistically expected in human tissues after oral 
administration caused a significant increase in intracellular cAMP, activated PKA, as 
well as in phosporylation of ERK.1/2 and CREB. Furthermore, the proliferation of cells 
was significantly stimulated by identical concentrations of B-carotene as monitored by 
MTT assays. 
These data are in accord with our earlier publications that have identified a beta­
adrenergic receptor-initiated growth-regulating pathway with cAMP as a downstream 
effector in human pulmonary adenocarcinomas of Clara cell lineage in vitro and in a 
hamster model. In light of the fact that pulmonary adenocarcinoma is the leading type of 
lung cancer, these findings suggest that the growth promoting effects of B-carotene on 
this cancer type observed in our experiments was an important factor responsible for the 
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unfortunate outcome of the CARET trial. This interpretation is supported by the fact that 
elevated levels of cAMP in the cardiovascular system play a major role in the genesis of 
cardiovascular disease, which was also greatly promoted in the CARET trial. 
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Figure 1. Effects of �-carotene (20 nM) on intracellular cAMP accumulation in 
SAEC and NCI-H322 cells. Following a 24 hour starvation period, the cells were 
incubated for 10 or 30 minutes with �-carotene. Cells in the control group were 
treated with the vehicle of P-carotene (DMSO). Analysis of cAMP was by 
competitive binding assay as outlined in the Materials and Methods. Bars 
represent mean values and standard errors of triplicate samples from three 
independent experiments expressed as normalized data ( controls were set as 100-
% ). Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple 
comparison test and two-tailed unpaired t-test. The increase in intracellular cAMP 
was significant (p<0.05 and 0.01) for SAECs at both time intervals tested and 












Figure 2A. Agarose gel exemplifying the effects of �-carotene (20 nM) on 
phosphorylation of PKA in SAECs and NCI-H322 cells. Following a 24 hour 
starvation period, the cells were exposed to �-carotene for the indicated times. 
PKA activity was then assayed in cell lysates using a Pep Tag assay for non­
radioactive detection of PKA and the samples were separated on an 0.8% agarose 
gel. Phosphorylated peptide migrated towards the positive electrode (+Ve), while 
non-phosphorylated peptide migrated towards the negative electrode (-Ve). 
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Figure 2B. Bar graph illustrating densitometry values of the bands in Figure 2A. 
Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 100%) mean values 
and standard errors of three independent experiments, each with triplicate 
samples. Statistical analysis of data was by one-way ANOV A, Tukey-Kramer 
multiple comparison test and two-tailed unpaired t-test. The observed increases in 
phosphorylated PKA were significant (p<0.001) at all time intervals tested in the 
SAECs and after 5, 15, and 30 minutes of exposure in NCI-H322 cells. 
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Figure 3A. Western blot exemplifying the effects of �-carotene (20 nM) on the 
expression of phosphorylated CREB and total CREB protein in SAECs. Following a 
24 hour starvation period, cells were exposed to b-carotene for the time intervals 
indicated. The bands for p-CREB increased in size and density over time whereas no 
increase was observed in the bands for total CREB protein. 
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Figure 3B. Western blot exemplifying the effects of �-carotene (20 nM) on the 
expression of phosphorylated CREB and total CREB protein in NCI-H322 cells. 
Following a 24 hour starvation period, cells were exposed to �-carotene for the 
time intervals indicated. The bands for p-CREB increased in size and density over 

















Figure 3C. Bar graph illustrating densitometry values of the bands in Figures 3A and 
3B. Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 100%) mean values and 
standard errors of three independent experiments, each with triplicate samples. 
Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple 
comparison test and two-tailed unpaired t-test. The observed increases in p-CREB 
were significant (p<0.001) in both cell systems at all time intervals tested. 
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Figure 4A. Western blot illustrating the effects of �-carotene (20 nM) on the 
expression of ERKl/2 and its phosphorylated form in SAECs. Cells were exposed to 
�-carotene for the time intervals indicated after a 24 hour starvation period. The 
bands for p-ERKl/2 increased in size and intensity, an effect that peaked after 30 
minutes of incubation whereas the expression of ERK 1 /2 did not increase. 
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Figure 4B. Western blot illustrating the effects of �-carotene (20 nM) on the 
expression of ERKl/2 and its phosphorylated form in NCI-H322 cells. Cells were 
exposed to �-carotene for the time intervals indicated after a 24 hour starvation 
period. The bands for p-ERK 1 /2 increased in size and intensity, an effect that peaked 
after 1 5  minutes of incubation whereas the expression of ERK 1 /2 did not increase. 









Figure 4C. Bar graph illustrating densitometry values of the bands in Figures 4A and 
4B. Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 100%) mean values and 
standard errors of three independent experiments, each with triplicate samples. 
Statistical analysis of data was by one-way ANOV A, Tukey-Kramer multiple 
comparison test and two-tailed unpaired t-test. The observed increases in p-ERKl/2 
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Figure 5. Effects of P-carotene ( lpM-200 nM) on cell number in SAECs and NCI­
H3 22 as assessed by MTT assay. The cells were left to grow in complete media for 5 
hours to attach. The cells were then switched to fresh low serum media (0.05% FBS) 
for SAECs and (0.1 % FBS) for NCI-H322 cells. Cells were then exposed for 72 hours 
to P-carotene at the concentrations indicated. Bars represent normalized ( control 
values set at 100%) mean values and standard errors of three independent 
experiments, each with four samples per group. Statistical analysis of data was by 
one-way ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t­
test. The observed increases in cell number were significant (p<0.001 )  at all 
concentrations tested in both cell systems. 
Inset: Inhibitory effects of the adenylase cyclase inhibitor SQ2536 (500 nM) or the 
MEK inhibitor PD98059 (10 µM) on P-carotene induced cell numbers as assessed by 
MTT assay. Following a 24 hour starvation period, cells were pre-incubated for ten 
minutes with the inhibitors and then exposed for 72 hours to P-carotene. The 
stimulatory response to P-carotene was significantly reduced (p<O.001) by both 
inhibitors in both cell systems. Bars represent normalized ( cells treated with P­
carotene alone set as 100%) mean values and standard errors of three independent 















Figure 6. Effects of �-carotene (lpM-2µM) on cell number in BEAS-2B cells as 
assessed by MTT assay. The cells were left to grow in complete media for 5 hours to 
attach. The cells were then switched to fresh low serum media (0.05% FBS). Cells 
were exposed for 72 hours to �-carotene at the concentrations indicated. Bars 
represent normalized (control values set at 100%) mean values and standard errors of 
three independent experiments, each with four samples per group. Cell numbers were 
significantly reduced at all concentrations tested (p< 0.001 by one way ANOVA, 
Tukey-Kramer multiple comparison test and two-tailed unpaired t-test). 
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PART IV: 
Theophylline stimulates cAMP-mediated signaling associated 
with growth regulation in human cells from pulmonary 
adenocarcinoma and small airway epithelia 
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Part IV 
Brief explanatory statement 
This chapter is a lightly revised version of a manuscript by the same name that has 
recently been submitted to the journal "International Journal of Oncology". 
Hussein, A., N., Al-Wadei1, Takashi Takahashi and Hildegard M. Schuller1 '3 • 
1 Experimental Oncology Laboratory, Department of Pathobiology, College of Veterinary 
Medicine, University of Tennessee, Knoxville, TN, USA and 2 Aichi Cancer Center 
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Knoxville, TN 3 7996 
Phone: 865-974-82 1 7  
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My use of "we" in this chapter refers to my co-authors and myself. My primary 
contributions to this paper include ( 1 )  selection of the topic, (2) development of assay 
conditions suitable to test the hypothesis that theophylline stimulates the growth of 
pulmonary adenocarcinoma cells and their normal cells of origin, (3) conduction of 
cAMP assays, ( 4) conduction of PKA activation assays, ( 5) conduction of Western blots, 
( 6) conduction of MTT assays, (7) analysis and interpretation of all data, (8) statistical 
analysis of all data, (9) photographic and graphic documentation of results, ( 1 0) 
conduction of comprehensive literature reviews, ( 1 1 )  writing of the manuscript (with 
some editorial assistance by Dr. Schuller) . 
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Introduction 
Preclinical studies in mouse models of lung cancer have demonstrated that green 
tea as well as black tea inhibit the development of experimentally induced lung adenomas 
and that this effect is largely caused by polyphenols of the catechin family that have 
antioxidant, anti-mutagenic, pro-apoptotitc and anti-proliferative effects in this animal 
model (1-4). However, epidemiological studies on the effects of tea in human 
populations have been inconclusive with some showing a reduction in lung cancer risk 
while others demonstrated no effect or even cancer promoting effects ( 5-7). 
Unfortunately, none of the epidemiological investigations have specified the effects of tea 
on histological lung cancer types. Among the four major histological lung cancer types 
( adenocarinoma, small cell lung carcinoma, squamous cell carcinoma, large cell 
carcinoma), pulmonary adenocarcinoma (PAC) is the leading type of lung cancer today 
(8, 9). Even though mouse lung adenoma is a model for human PAC, it is well 
established that these mouse tumors are derived from alveolar type II cells (10, 11). By 
contrast, electron microscopic investigations have provided evidence for about 90% of 
human PACs to be derived from bronchial and bronchiolar Clara cells (PACC) with only 
about 10% of cases exhibiting characteristics of alveolar type II cells (12). Accordingly, 
preclinical data generated in the mouse models cannot be extrapolated to about 90% of 
cases of the leading type of human lung cancer (PACC). 
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Studies conducted in our laboratory have shown that human cell lines derived 
from P ACC as well as experimentally induced P ACC in hamsters are under �-adrenergic 
growth control ( 1 3- 1 6). Pharmacological agonists of �-adrenergic receptors as well as 
forskolin, which stimulates the downstream effector of this receptor family, cAMP, each 
demonstrated strong promoting effects on human P ACC cell growth in vitro and on the 
development of P ACC in hamsters. We have also shown that a cell line derived from 
human PAC of alveolar type II cell lineage responded with an inhibition in cell 
proliferation to forskolin ( 1 6). These findings suggest that within the family of human 
PA Cs the predominating Clara cell derived tumors respond with increased growth to 
cAMP whereas the rare PAC of alveolar type II cell lineage is inhibited. Accordingly, 
any agents that increase intracellular cAMP have the potential to act as tumor promoters 
for the development of PACC. 
Theophylline is a methylxanthine contained in tea products and in numerous 
medications for the treatment of asthma, cough and the common cold ( 1 7). Among the 
tea products that contain theophylline are grean tea, black tea, mint tea (all in their 
caffeinated and decaffeinated forms) as well as numerous dietary supplements that are 
based on green tea extracts and which are widely used as weight control medicines. It is 
well established that theophylline inhibits the enzyme phopsphodiesterase that mediates 
the cellular break-down of cAMP ( 17). Consequently, exposure to theophylline results in 
intracellular accumulation of cAMP. It is therefore reasonable to assume that signaling 
pathways downstream of cAMP will be stimulated by theophylline. In light of the tumor 
promoting effects of cAMP on human and hamster PACC discovered by us, theophylline 
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may therefore selectively promote the growth and development of this form of lung 
cancer. 
In support of this hypothesis, our current data in cell lines derived from human 
P ACC and its cell of origin (SAEC) show that theophylline increased intracellular cAMP 
resulting in the activation of its downstream kinase, protein kinase A (PKA) and its 
associated transcription factor cAMP response element binding protein (CREB) as well 
as phosphorylation of the mitogen-activated protein kinases ERK.1/2. 
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Materials and Methods 
Cell lines and tissue culture 
The human PAC cell line with characteristics of Clara cells, NCI-H322 (Center 
for Applied Microbiology and Research (ECACC, Salisbury, Wiltshire, UK) was 
maintained in RPMI-1640 medium (Gibco Invitrogen-Life Technologies, Carlsbad, CA) 
supplemented with 10% FBS, 10 mM Hepes, lmM sodium pyruvate, 2mM L-glutamine, 
4500 mg/I glucose, and 1500mg/I sodium bicarbonate. The Simian virus 40 (SV 40)­
immortalized human peripheral airway cell line HPLlD  (18), referred to in this 
publication as small airway epithelial cells SAEC, was provided to us by Dr. Takashi 
Takahashi (Aichi Cancer Center Research Institute, Nagoya University, Chikusa-ku, 
Nagoya, Japan). These cells were maintained in F-12 (HAM) medium buffered with 
15mM HEPES (pH 7.3; Gibco Invitrogen-Life Technologies, Carlsbad, CA) and 
supplemented with 5 µg/ml bovine insulin, 5 µg/ml human transferrin, 1 f
f 7 M 
hydrocortisone, 2 x10- 10 M triiodothyronine (Cambrex Bio Science Walkersville, Inc, 
Walkersville, MD) and 1 % fetal calf serum (FCS; ATCC, Manassas, VA). No antibiotic 
was added. 
cAMP Immunoassay 
Cells were plated at 4 x 105 cells per well in 6-well plates and grown in F-12 
media with supplements and 1 % FBS for SAECs or in RPMI-1640 containing 10% FBS 
until 65-70 % confluence. Then cells were then washed twice with IX PBS and then fed 
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with low serum (0.05% FBS) for SAECs and (0. 1 % FBS) for NCI-H322 cells or no­
serum medium for 24 hours starvation. Fresh low serum media of F 12  (0.05% FBS) or 
RPMI media (0. 1  % FBS) containing lmM IBMX, a phosphodiesterase inhibitor was 
added to all treatment and control group and pre-incubated for 30 minutes. After removal 
of this pre-incubation mix, the cells were incubated and treated with the concentrations of 
theophylline indicated in the figure legend in the appropriate medium containing lmM 
IBMX for 1 0  minutes. After three washes with water, cells were incubated with 0. 1 M 
HCL lysis buffer for 20-30 minutes, and then the cells were scraped by plastic scraper 
and collected into 1 .5ml eppendorf tubes, then lysed by sonication. Samples were then 
vortexed immediately before being analyzed for cAMP levels using a direct cyclic AMP 
enzyme immunoassay kit according to the manufacturer instructions (Assay Designs Inc). 
Briefly, the assay utilizes p-nitrophenyl phosphate as a substrate and a polyclonal 
antibody to cAMP to bind, in a competitive manner, the cAMP in sample that has cAMP 
covalently attached to it. Reactions were stopped with trisodium phosphate and color 
intensity was measured at 405 nm. 
Data are expressed as mean values and standard errors of three independent 
experiments, each conducted with triplicate samples per treatment group. Statistical 
analysis of data was by one-way ANOV A, Tukey-Kramer multiple comparison test and 
two-tailed unpaired t-test. 
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PKA activation assay 
Following incubation of cells with theophylline ( 10 pM) for 5 minutes to 1 hour 
as specified in the figure legends, PKA activity was assayed in cell lysates using a Pep 
Tag assay for non-radioactive detection of activated PKA (Promega Corperation, 
Madison, WI, USA), following the instruction of the manufacturer. This assay utilizes 
fluorescent substrate for PKA that changes the peptide's net charge upon phosphorylation 
of PKA, thus allowing the phosphorylated peptide to migrate to the positive electrode(+), 
while the non-phosphorylated peptide migrates to the negative electrode (-). Briefly, 
reactions containing a brightly colored fluorescent peptag Al  peptide (0.4µg/µl), peptide 
protection and PKA activator solutions were incubated in ice for few min before lmin 
incubation at 30
°
C. After adding samples, reactions were incubated at room temperature 
for 30
° 
min, boiled at 95
° 
C for 10 min, and loaded onto 0.8% agarose gel in 50 mM Tris­
HCl (pH 8.0). At this point the qualitative assay is complete, and the protein kinase A 
activity in samples was determined by examining the gel under UV lights. Densitometric 
analysis of the bands was conducted using NIH Scion software for image quantitation. 
Data are expressed as mean values and standard errors of three independent 
experiments, each with triplicate samples per treatment group. Statistical analysis of data 
was by one-way ANOVA, Tu.key-Kramer multiple comparison test and two-tailed 
unpaired t-test. 
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Assessment of total proteins and phosporylated proteins by Western blotting 
To assess the effects of theophylline ( 10  pM) on the expression and 
phosphorylation of the mitogen activated protein kinases ERKl/2 or the cAMP response 
element binding protein CREB, 500,000 NCI-H322 or SAEC cells were seeded into 
culture vessels ( 100 cm2) containing their respective growth media. When the cells had 
reached 60-65% confluence, they were rinsed one time with lX PBS and serum-starved 
for 24 hours. Following removal of the media and replacement with fresh low-serum 
media, theophy lline ( 10 pM) was added to the culture vessels and cells were incubated 
from 5 minutes to 1 hour as detailed in the figure legends. The cultured cells then were 
washed once with cold PBS, lysed in 20 mM Tris-base, 200 mM NaCl, 1 M sodium 
fluoride. 0.5 M EDTA, 1 00 mM Na3V04, 100 mM PMSF, 1µ1 pepstatin, 1 µl leupeptin, 1 
µI aprotinin, and 0.25 % NP-40. Then, protein samples were denatured by boiling at 
95°C for 5 min, separated on 10% SDS-PAGE, and transferred to nitrocellulose. 
Membranes were blocked with 5% non-fat dry milk, probed with rabbit polyclonal CREB 
and phosphorylated CREB antibodies, respectively, and developed by 
chemiluminescence with ECL reagentsMembranes were blocked in 10ml of 5% non-fat 
dry milk (Kroger) in lX TBST for 1 hour. Membranes were then incubated over night at 
4°C with primary antibodies at a 1 :1000 dilution (rabbit polyclonal for total ERKl/2, 
rabbit polyclonal for Thr202/Tyr204 phosphorylated Erk l/2; rabbit polyclonal for total 
CREB, mouse monoclonal for SER33 phosphorylated CREB; Cell Signaling 
Technology, Beverly, MA). Equal loading of lanes was confirmed by blotting for actin 
using mouse actin monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO, USA). 
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Data are expressed as mean values and standard errors of three independent 
experiments, each conducted with triplicate samples per treatment group. Statistical 
analysis of data was by one-way ANOV A, Tukey-Kramer multiple comparison test and 
two-tailed unpaired t-test. Following statistical analysis, data were normalized with 
controls set as 100% for documentation as column graphs. 
Assessment of cell numbers by MTT assay 
The effects of theophylline on cell proliferation were assessed by the 
colorimetric 3-( 4, 5-dimethyle thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay (2) (Sigma-Aldrich Co., St. Louis, MO, USA). Briefly, the MTT test is based on 
the NADH-dependent enzymatic reduction of the tetrazolium salt MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide] in metabolically active cells 
but not in dead cells. Cells were seeded into 6-well tissue culture plates (Falcon, 
Franklin Lakes, NJ, USA) at a density of 50,000 cells per well for NCI-H322, and 
50,000 cells per well for SAEC. The cells were left to grow in complete media at 3 7°C 
with 5% CO2 for 5 hours to attach. The cells were then switched to fresh low serum 
media and theophylline was added at the concentrations specified in the figure legend 
and incubated for 72 hours. Fresh low serum medium of each cell line and fresh 
treatment were added every other day. After treatment for 68 hours 50µ1 of [3-( 4, 5-
dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (0.5mg/ml) was dissolved in 
RPMI-1640 with L-glutamine and phenol-free medium (Gibco Invitrogen Corporation, 
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Grand Island, N.Y, USA)], added to the medium and incubated at 37°C in the incubator 
for another 2-3, allowing for the metabolic conversion of the MTT substrate to blue 
formazan. The media were then discarded and 550 µl of Isopropanol (2-propanol UV 
cutoff 205 nm, Fisher Scientific, GA, USA) was added to the wells. Absorbances at 570 
nm and 630 nm in each well were measured on a micro-ELISA. Data are expressed as 
mean values and standard errors of three independent experiments, each conducted with 
four samples per treatment group. Statistical analysis of data was by one-way ANOV A, 
Tu.key-Kramer multiple comparison test and two-tailed unpaired t-test. 
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Results 
Exposure of the putative cells of origin of pulmonary adenocaricnoma, SAECs, 
for ten minutes to theophy Hine caused a significant and concentration-dependent increase 
in intracellular cAMP as assessed by immunoassay (Figure 1 ). This response peaked at 
the 10, pM concentration a 2.2-fold increase. Similarly, the human PAC cell line NCI­
H322 responded with a 2.1-fold increase in intracellular cAMP when exposed to 10 pM 
theophylline (Figure 1 ). The observed stimulation of cAMP was reproducible as assessed 
by three independent experiments that yielded similar results, each with three samples per 
treatment group. Because cAMP levels peaked in both cell systems after expoure to 10  
pM theophy Hine, this concentration was used in assays for the assessment of PKA 
activation and phosphorylation of CREB and ERK.1/2. Statistical evaluation of the data 
by one-way ANOVA, Tukey-Kramer multiple comparison test and paired two-tailed t­
test established significant differences between control and treatment groups at all 
theophyline concentrations tested in both cell systems. 
Assessment of PKA activation by a non-radioactive kit that measures the 
migration of the phosphorylated peptide to the positive electrode(+), while the non­
phosphorylated peptide migrates to the negative electrode (-), revealed a time-dependent 
increase in activated PKA of SAECs exposed to theophylline (10 pM; Figure 2) with a 
maximum 5-fold increase at the 5 minute time interval (Figure 2). Similarly, the human 
PAC cell line NCI-H322 responded to 10 pM of theophylline with a time-dependent 
increase of PKA activity that peaked with a 4.97--fold increase at the 15 minute time 
interval (Figure 2). In SAECs, the observed increase in PKA activity was highly 
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significant at all time interval tested (p< 0.00 1 by one way ANOVA, Tukey-Kramer 
multiple comparison test and unpaired, two-tailed t-test from triplicate samples per 
treatment group of three independent experiments). In NCI-H322 cells, no increase in 
PKA activity was observed after 5 minutes of exposure to theophylline whereas the 
increase in PKA acitity was highly significant (p<0.00 1 )  after expoure for 1 5, 30, or 60 
minutes. 
The effects of theophylline ( 1 0  pM) on expression levels of the transcription 
factor CREB and its phosphorylated form were assessed by Western blot analysis (Figure 
3 ). SAECs demonstrated a time-dependent increase in p-CREB protein with the highest 
level (5 .35-fold-fold increase) observed after 1 5  minutes of exposure (Figure 3). NCI­
H322 cells were similarly responsive to theophylline with a 5 .45-fold increase in p­
CREB observed after 15  minutes of exposure (Figure 3). In neither cell line did exposure 
to theophylline increase the levels of unphosphorylated CREB protein (Figure 3). The 
observed increases in p-CREB expression were highly significant in both cell systems at 
all time intervals tested (p<0.001 by one way ANOV A, Tukey-Kramer multiple 
comparison test and two-tailed unpaired t-test from mean values and standard errors of 
densitometric values from three independent experiments conducted under identical 
conditions, each with triplicate samples). 
The effects of theophylline ( 1 0  pM) on the mitogen-activated kinases ERKl/2 and 
their phosphorylated forms were also assessed by Western blotting. As exemplified in 
Figure 4, p-ERKl/2 was significantly increased in SAECs after 5, 1 5  or 30 minutes of 
exposure to theophylline with peak values (3 .5-fold increase) at the 5 minute time 
interval (Figure 4). The response of the cancer cell line NCI-H322 to theophylline was 
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similar, with a 3 .3-fold increase in p-ERK.1/2 expression after 5 minutes of exposure 
(Figure 4) . The observed increases in p-ERK.1/2 in both cell lines cells were highly 
significant (p<0.00 1 )  for SAECs at them 5, 1 5  and 30 minute time intervals and for NCI­
H322 at all time points tested (one-way ANOVA, Tukey-Kramer multiple comparison 
test and two-tailed unpaired t-test from densitometric values of three independent 
experiments conducted under identical conditions, each with triplicate samples). 
Theophylline did not increase the expression of unphosphorylated ERK.1/2 protein in 
either cell system at any of the time intervals tested. 
The potential role of the observed changes in cAMP, PK.A, and phosporylated 
proteins on cell proliferation was assessed by MTT assays. In our published studies on 
the growth-stimulating effects of P-adrenergic agonists and cAMP on NCI-H322 cells we 
used [3H]-thymidine incorporation assays that monitor DNA synthesis ( 1 3 , 1 6) . Because 
the MTT assay monitors numbers of viable cells which can be influenced by both, cell 
proliferation and apoptosis, the results of the MTT assays were verified by [3H]thimidine 
incorporation assay with controls versus three concentrations ( 1 pM, 1 0  pM, 1 00 pM) of 
theophylline (data not shown) . We tested the effects of theophylline on cell numbers in 
the MTT assay after 24, 48 or 72 hours of incubation. While the stimulating effects of 
theophylline were highly significant at all time intervals tested in SAECs, the responses 
after 72 hours of exposure were the most dramatic and are therefore illustrated in Figure 
5 .  Our data show that theophylline caused a dramatic increase in the numbers of SAECs 
particularly at the low concentrations, an effect that peaked with a 2.9-fold increase after 
incubation with a 1 pM concentration (Figure 5). Under the condition of our experiments, 
the cancer cell line NCI-H322 were less responsive, with a small but significant increase 
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in cell numbers at 10 and 100 nM concentrations of theophylline. The stimulatory effects 
of theophylline on cell proliferation in SAECs were highly significant (p< 0.001) while 
very significant (p< 0.01) in NCI-H322 cells by one-way ANOVA, Tukey-Kramer 
multiple comparison test and two-tailed unpaired t-test. 
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Discussion 
Theophylline is contained in green tea, black tea and mint tea as well as in a host 
of asthma therapeutics, over the counter cold medicines ( 1 7) and dietary supplements 
that target weight loss via green tea extracts. Even though the conflicting data on the 
tumor modulating effects of tea (5 , 6) implicate that ingredients in this family of 
beverages may have beneficial effects on some cancers while promoting others, the 
potential tumor modulating effects of theophylline have not been given attention in past 
research. The discovery that the leading type of lung cancer, PACC, is regulated by a 
pathway initiated by �-adrenergic receptors and involving the stimulation of cAMP ( 1 3, 
1 4, 1 6, 1 9) strongly suggests that phosphodiesterase inhibitors such as theophylline , 
which increase intracellular levels of cAMP, may act as selective promoters of this cancer 
type. In support of this hypothesis, our current data show that theophylline significantly 
increased intracellular cAMP, activated PKA, phosphorylated CREB and phosphorylated 
ERK.1/2 in SAECs and NCI-H322 cells. SAECs additionally responded with a highly 
significant increase in cell number suggestive of increased cell proliferation. The lack of 
proliferative response of NCI-H322 cells to theophylline is a reflection of a very strong 
autocrine growth stimulation via production of EGF that has developed in this cell line 
under prolonged in vitro passages. Unfortunately, early passage material of this cell line 
is no longer available. 
The growth-stimulating effects of theophylline observed in SAECs and PAC cells 
are in accord with published data that have documented a stimulation of cell proliferation 
of human PAC cells in vitro in response to agents that increase intracellular cAMP ( 1 3 ,  
1 00 
1 6). A cancer promoting effect of agents that increase intracellular cAMP has also been 
documented in a hamster model of PAC induced by the tobacco-specific carcinogen 
NNK ( 14, 19). By contrast, such agents inhibited the growth of human PAC cells of 
alveolar type II cell lineage ( 16) or human small cell lung cancer cells (20) and 
demonstrated significant cancer preventive effects in a hamster model of NNK-induced 
neuroendocrine lung tumors ( 19). 
Collectively, our current data and published evidence emphasize the fact that 
identical pathways can have very different functions in different cell types and in cancers 
of different cell lineages. Strategies that target regulatory signal transduction pathways 
for the prevention and therapy of cancer have to carefully consider this. Unless suitable 
diagnostic tools are developed that identify which signaling pathway is hyperactive in 
individual patients, clinical trials aimed at modulating signal transduction will continue to 
yield disappointing results. 
1 0 1  
Summary 
The methy lxanthine theophy Hine is contained in tea and in numerous asthma and 
cold medications. Theophylline inhibits the enzyme phosphodiesterase, thereby 
preventing the intracellular break-down of cAMP. The resulting increase in intracellular 
cAMP reduces smooth muscle tone, thus dilating the airways. Epidemiologic studies on 
· preventive effects of tea on the development of lung cancer have yielded mixed results, 
with some studies demonstrating a reduction in lung cancer risk whereas others showed 
evidence for cancer promotion. On the other hand, preclinical studies in mouse models of 
lung cancer or in vitro systems have consistently demonstrated strong cancer preventive 
effects of tea and of polyphenols contained in tea. 
Investigations conducted in our laboratory have recently shown that cell lines 
derived from human pulmonary adenocarcinomas of Clara cell lineage (P ACC) and 
experimentally induced P ACCs in a hamster model are under �-adrenergic growth 
control. Beta-adrenergic agonists as well as forskolin, which activates cAMP, had strong 
growth-promoting effects on human P ACC cells and on the hamster P ACCs. The current 
project therefore tests the hypothesis that theophylline activates growth-stimulating 
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Figure 1 .  Effects of theophylline ( 10  minutes) on intracellular cAMP 
accumulation in SAEC and NCI-H322 cells. Following a 24 hour starvation 
period, the cells were incubated for 1 0  minutes with theophy lline at the indicated 
concentrations. Analysis of cAMP was by competitive binding assay as outlined 
in the Materials and Methods. Bars represent mean values and standard errors of 
triplicate samples from three independent experiments expressed as normalized 
data ( controls were set as 100- % ). Statistical analysis of data was by one-way 
ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t-test. 
The increase in intracellular cAMP was significant (p<0.0 1 )  at all theophylline 
concentrations tested in both cell systems. 
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Figure 2A. Agarose gel exemplifying the effects of theophylline (10 pM 
incubated for 5 to 60 minutes) on phosphorylation of PKA in SAECs and NCI­
H322 cells. Following a 24 hour starvation period, the cells were exposed to 
theophylline for the indicated times. PKA activity was then assayed in cell lysates 
using a Pep Tag assay for non- radioactive detection of PKA and the samples 
were separated on an 0.8% agarose gel. Phosphorylated peptide migrated towards 
the positive electrode (+Ve), while non-phosphorylated peptide migrated towards 
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Figure 2B. Bar graph illustrating densitometry values of the bands in Figure 2A. 
Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 100%) mean values 
and standard errors of three independent experiments, each with triplicate 
samples. Statistical analysis of data was by one-way ANOVA, Tukey-Kramer 
multiple comparison test and two-tailed unpaired t-test. The observed increases in 
phosphorylated PKA were significant (p<0.001) at all time intervals tested in the 
SAECs and after 15, 30 and 60 minutes of exposure in NCI-H322 cells. 
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Figure 3A. Western blots exemplifying the effects of theophylline (10 pM) on the 
expression of phosphorylated CREB and total CREB protein in SAECs or NCI-H322 
cells. Following a 24 hour starvation period, cells were exposed to theophylline for 
the time intervals indicated. The bands for p-CREB increased in size and density over 
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Figure 3B. Bar graph illustrating densitometry values of the bands in Figures 3A. 
Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 1 00%) mean values and 
standard errors of three independent experiments, each with triplicate samples. 
Statistical analysis of data was by one-way ANOVA, Tukey-Kramer multiple 
comparison test and two-tailed unpaired t-test. The observed increases in p-CREB 
were significant (p<0.001 )  in both cell systems at all time intervals tested. 
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Figure 4A. Western blots illustrating the effects of theophylline (exposures from 5 
minutes to 60 minutes, 1 0  pM) on the expression of ERK.1/2 and its phosphorylated 
form in SAECs and NCI-H322 cells. Cells were exposed to theophylline for the time 
intervals indicated after a 24 hour starvation period. The bands for p-ERK 1 /2 
increased in size and intensity, an effect that peaked after 5 minutes in both cell 
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Figure 4B. Bar graph illustrating densitometry values of the bands in Figure 4A. 
Densitometric analysis was performed using the NIH Scion software for image 
quantitation. Bars represent normalized ( control values set at 1 00%) mean values and 
standard errors of three independent experiments, each with triplicate samples. 
Statistical analysis of data was by one-way ANOV A, Tu.key-Kramer multiple 
comparison test and two-tailed unpaired t-test. The observed increases in p-ERK.1/2 
were significant (p<0.00 1 )  in NCI-H322 cells at all time intervals tested and in 
SAECs after 5, 1 5 , and 30 minutes. 
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Figure 5. Effects of theophylline ( lpM-1 µM) on cell number in SAEC and NCI­
H322 cells as assessed by MTT assay. The cells were left in complete media for 5 
hours to attach. The cells were then switched to fresh low serum media (0 .05% FBS) 
for SAECs and (0. 1 % FBS) for NCI-H322. Cells were then exposed for 72 hours to 
theophylline at the concentrations indicated. Bars represent normalized (control 
values set at 1 00%) mean values and standard errors of three independent 
experiments, each with four samples per group. Statistical analysis of data was by 
one-way ANOV A, Tukey-Kramer multiple comparison test and two-tailed unpaired t­
test. The observed increases in SAECs were significant (p<0.00 1 )  at concentrations 
from 1 pM to 1 0  nM. The PA Cs were less responsive, with a small but significant 
(p<0.0 1 )  increase at the 1 0  and 1 00 nM concentrations. 
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